Director greeting

The role of pharmacists in connecting hospitals to communities

Kobe City Municipal Medical Center
Kobe City Medical Center
Pharmacy Department Director
Nobuyuki Muroi

We pharmacists are committed to providing safe and effective drug therapy. We provide continuous pharmaceutical management, from patient medication instructions to monitoring side effects, in all aspects of drug therapy, including in the dispensing room, pharmacist outpatient clinic, pre-hospitalization preparation center, emergency medical center, chemotherapy center, ward drug administration during hospitalization, and drug administration in the operating room. We also consider the daily life of each patient and deepen our collaboration with insurance pharmacies to support the health of patients so that they can continue their drug therapy with peace of mind even after being discharged from the hospital. Furthermore, we scientifically analyze drug profiles through research on pharmacokinetics and reactivity after administration and side effect countermeasures, and promote efforts to improve the therapeutic effects of drugs and reduce side effects, thereby developing safe drugs.

Keeping in mind that “Where there is medicine, there is a pharmacist,” all pharmacy department members will work together to ensure that patients are satisfied with their peace of mind. If you have any questions or concerns about your medicine, please feel free to ask your pharmacist.

April 2024

Pharmacy staff

April 2024

Pharmacy Department Director Nobuyuki Muroi
Deputy Director of Pharmacy Department Hiroaki Ikesue
Deputy Director of Pharmacy Department Manabu Kume
Deputy Director of Pharmacy Department Masaki Oyama
Chief of Pharmacy Department Toshihiko Oda
Chief of Pharmacy Department Mieko Ohne
Assistant to Hospitl Director and Counsilor Toru Hashida

In addition, 12 chief inspectors and 2 senior inspectors
Full-time pharmacists: 69 in total, 9 pharmacist residents

pharmacist 69 (full-time), 3 (part-time)
Pharmacist Resident 9 people
Clerk / pharmacy assistant 10 people
total 91 people (81 pharmacists)

Guidance, specialty, certified pharmacist

April 2024

Japan Pharmaceutical Society Instruction pharmacist Five people
Pharmacist specializing in medical pharmacy 9 people
Cancer guidance pharmacist 1 person
Oncology pharmacist 6 people
Drug therapy specialist pharmacist 1 person
Japan Hospital Pharmacists Association Cancer drug therapy certified pharmacist 2 people
HIV infection certified pharmacist 1 person
Infection Control Certified Pharmacist 2 people
Certified pharmacist of Nichiyaku Hospital 32 people
Lifelong Training Certified Pharmacist 11 people
Japanese Society of Clinical Oncology Outpatient cancer treatment certified pharmacist 3 people
Diabetes Educator Certification Organization diabetes educator Five people
Japanese Society of Medicine and Diabetes Diabetes drug therapy certified pharmacist 2 people
Japan Society of Medical Informatics medical information technician 1 person
Japanese Society of Palliative Medicine Palliative pharmacotherapy certified pharmacist 3 people
Temporary Guidance Pharmacist for Palliative Medicine 2 people
Narcotics education certified pharmacist 1 person
Japanese Society for Clinical Nutrition and Metabolism NST Professional Therapist Five people
Perioperative/Emergency Intensive Care Therapist 1 person
Japanese Society For Emergency Medicine Emergency certified pharmacist 2 people
Japan Gerontological Society Geriatric Pharmacy Licensed Pharmacist 1 person
Japanese Society for Clinical Toxicology Certified Clinical Toxicologist 1 person
Japanese Society of Clinical Pharmacology Certified CRC 2 people
Japanese Society of Chemotherapy Antibacterial chemotherapy certified pharmacist 3 people
The Japanese Circulation Society heart failure educator 2 people
Japan Kidney Association renal failure educator 1 person
Japan Pharmacist Training Center Training certified pharmacist 4 people
Certified Practical Training Guidance Pharmacist 9 people
Pediatric drug therapy certified pharmacist 2 people
Chinese herbal medicine and herbal medicine certified pharmacist 2 people
Certified by the Japan Clinical Nutrition Association NR/Supplement Advisor 1 person
Disease Control Division, Health Bureau, Health and Welfare Department Hyogo Prefecture hepatitis medical coordinator 1 person
Hyogo Prefecture Federation of Diabetes Educators Diabetes Educator Hyogo 2 people
Japanese Society of Anesthesiologists Perioperative management team pharmacist 1 person
Japan Rheumatism Foundation Registered pharmacist at the Rheumatism Foundation 1 person
Japanese Society of Parkinson's Disease and Movement Disorders Parkinson's disease educator 2 people

About the duties of the pharmacy department

prescription dispensing

By operating a dispensing system (dispensing audit system, automatic medicine bag creation, automatic tablet packaging, prescription audit system) linked to the electronic medical record system for both inpatients and outpatients, we are working to ensure accurate dispensing and efficiency in dispensing. . In addition, the introduction of a prescription drug delivery system has made it possible to deliver drugs quickly and accurately. In 2021, we will introduce a robot dispensing room (automatic drug picking device, powdered drug dispensing robot, picking support system) to digitize dispensing.

automated drug picker Drug Station
Picking support system NEW PORIMS
Dispensing audit

injection drug dispensing

Using an automated injection dispensing device linked to the injection drug ordering system, injections are dispensed in trays on a daily basis for each patient and each administration in all wards except the intensive care unit. We strive to provide safe injections by checking the patient's condition, dosage, administration method, compounding changes, side effects, etc. In addition, to ensure accurate dispensing, we introduced an injection picking support system in 2023.

Injection automatic dispensing device Ampoule picker
Injection drug audit

Aseptic preparation of injectable drugs

For all outpatient and inpatient cancer chemotherapy treatments, after checking the prescription contents, we carry out aseptic preparation in a safety cabinet. In 2017, we introduced an anticancer drug preparation robot to further improve efficiency. In addition, high-calorie infusions, which need to be mixed aseptically, are prepared in a clean bench.

Chemotherapy Audit Office
Chemotherapy sterile preparation room
Anticancer drug mixture preparation robot ChemoRo

formulation

In-house preparations are prepared when prescription drugs sold by pharmaceutical companies cannot meet the diverse needs of patients according to their illness. In-house preparations are those that are essential for the treatment of certain patients but are not sold by pharmaceutical companies due to reasons such as not being profitable, and are prepared at the request of doctor after reviewing them within the hospital.

Like high calorie infusion preparation
Preparing a high-calorie infusion

Drug management guidance work, ward pharmacy work

We have pharmacists in all wards, including the emergency center and intensive care unit. We provide medication instructions at the patient's bedside, and strive to provide safe and effective drug therapy by helping patients improve their adherence, supporting self-management, and suggesting prescriptions to avoid side effects. In addition, we actively participate in local medical care through various educational classes (patient classes) and other programs.

General Patient Support Department

Pre-hospitalization preparation center operations

Before hospitalization, we check the use of regular medications, health foods, and supplements to identify medications to be discontinued before surgery, in order to facilitate smooth treatment after hospitalization. We also check medications prescribed at other medical institutions to check for duplications and interactions. In addition, pharmacists are involved in the Perioperative Support Center, which opened in 2021 with the aim of helping patients undergo surgery recover quickly and return to society.

Discharge support services

Pharmacists at Regional Medical Cooperation Center and ward pharmacists work together to participate in discharge support conferences and joint discharge guidance (pre-discharge conferences) and support patients in taking medication at home in a way that suits their lifestyle so that they can continue their drug treatment with peace of mind even after being discharged.In addition, we strive to ensure that patients can receive safe and effective drug therapy even after being discharged by creating inter-facility drug information sheets for the medical institution to which they are transferred and by cooperating with medical institutions and insurance dispensing pharmacies.

Pharmacist collaboration work

Hospital pharmacists and insurance pharmacy pharmacists work together to ensure adherence by providing individualized medication instructions. One of the causes of re-admission due to worsening conditions in heart failure patients is decreased adherence, and in response, from 2023, pharmacists have begun collaborating with insurance pharmacies to use tracing reports for heart failure patients.

Drug concentration monitoring (TDM)

We conduct analyses based on blood concentration measurements of antibacterial drugs, mainly anti-MRSA drugs such as vancomycin and teicoplanin, antifungal drugs, and immunosuppressants. By setting optimal dosages for each patient, we contribute to ensuring efficacy and preventing the occurrence of side effects.
State of TDM work

Medicine management

We use an inventory management system to efficiently manage the purchase, storage, and supply of pharmaceuticals to each department. Pharmacists regularly check the pharmaceuticals in each department and strive to manage them appropriately, including quantities and expiration dates.

drug control

Although they have excellent analgesic effects, medical narcotics are pharmaceuticals that require strict management. Their handling and storage methods are strictly regulated, and we promote the management and proper use of medical narcotics within the hospital in accordance with the law. In addition, we have installed real-time drug management devices (Litera) in all operating rooms, allowing for 24-hour drug management. Furthermore, pharmacists stationed at the operating room satellite pharmacy work together with ward pharmacists to manage pharmaceuticals, contributing to high-quality perioperative medical care.

Pharmaceutical information management

We obtain pharmaceutical information necessary for the proper and safe use of pharmaceuticals from ministry of Health, Labor and Welfare notation and Welfare, the Pharmaceuticals and Medical Devices Agency (PMDA), pharmaceutical manufacturers and literature, and after evaluating and organizing it, we cooperate with pharmacists in each department to provide the information. For information of high urgency and importance, such as emergency safety information and safety flash reports, we check the usage status of the relevant pharmaceutical and provide the information promptly to doctor and other hospital staff. In addition, we also support pharmacists in each department, respond to questions and inquiries from hospital staff, and support the Pharmaceutical Affairs Committee Secretariat work and side effect reporting.
State of drug information room

Clinical trial/clinical research support

The Clinical Research and Innovation the development of new treatment methods, drugs and medical devices, and the optimization of existing medical technology. As the core of the administration and support department, pharmacists provide support services for the safe and smooth conduct of ethical and scientifically high-quality clinical trials and clinical research. In addition to proper management of investigational drugs, we also collect and manage safety-related information and other information.

Pharmacist outpatient

We are working to improve services for outpatients by explaining medications to them and checking for side effects, as well as keeping track of the regular medications of patients who are scheduled to be admitted to hospital.
Giving instructions on how to take medication
Oral medicine confirmation outpatient

At specialized booths or the Pre-Hospitalization Preparation Center, we check the patient's regularly-used medications before they are admitted to hospital, check whether they are used at our hospital, introduce alternative medications, and confirm whether medications have been discontinued before surgery.

Oral anticancer drugs pharmacist outpatient clinic / Interstitial pneumonia pharmacist outpatient clinic

Before consulting with doctor, we check the patient's medication status and side effects of anti-cancer drugs and interstitial pneumonia medication, record the patient's condition in the medical record, and make prescription suggestions to doctor if necessary.

Hepatitis C drug pharmacist outpatient

In order to maximize the effects of direct-acting antiviral drugs, which are therapeutic drugs for hepatitis C virus, interactions with regular drugs should be minimized, necessary medication instructions should be given, and medication status should be checked. In addition, it is explained that the risk of cirrhosis and liver cancer remains even after recovery, and the necessity of continued examination and examination is also explained.

Thalidomide/Lenalidomide/Pomalidomide Outpatient pharmacist
For patients prescribed thalidomide, lenalidomide, or pomalidomide, we provide guidance on the appropriate use and management of the medication, check the medication management status, and help them deepen their understanding of the importance of taking the medication.
Outpatient medication guidance
HIV medication pharmacist outpatient clinic

We support smooth treatment by conducting interviews at any time to check for side effects of HIV medication, concerns about the disease, etc. When first prescribing, we interview before doctor 's consultation and propose the appropriate medication.

Participation in team medical care

I am active in various situations as a member of the medical team.

Outpatient chemotherapy team

We contribute to the implementation of safe and secure cancer chemotherapy by checking anticancer drug prescriptions, managing regimens, preparing aseptic preparations, explaining side effects to patients, etc. We also work with insurance pharmacies to support the safe continuation of anticancer drug treatment in outpatient clinics.

HIV/AIDS support team

We work in collaboration with other professions to provide various types of support to patients regarding mental anxiety and physical disabilities that may arise from having to take medications over long periods of time over their lives, such as medications that require careful administration, medications that have specific side effects, or medications that are large and difficult to swallow.

palliative care team

We attend consultations at the palliative care outpatient clinic, propose prescriptions to doctor for symptom relief, and provide medication instructions to patients. For hospitalized patients who have been consulted by the palliative care team, we work with team members to understand their daily symptoms and provide pharmaceutical interventions for various clinical problems to alleviate symptoms.

Nutrition Management Team (NST)

We work together with other professions to ensure that all patients receive appropriate nutritional management, which is the foundation of their treatment. At core team conferences and satellite NSTs in the wards, we make proposals from a pharmaceutical perspective on parenteral nutrition planning, electrolyte management, complications, etc., and also participate in educational activities.

Infection Control Team (ICT)

We strive to prevent nosocomial infections by utilizing the expertise of pharmacists, such as advice on the proper use of antibacterial drugs and disinfectants, usage statistics, and TDM.

Antimicrobial Stewardship Team (AST)

We have dedicated pharmacists on staff to provide support to ensure optimal treatment of infectious diseases, including promoting the appropriate use of antibiotics.

risk management

In order to improve the quality and safety of medical care, we participate in the activities of Risk Management. In addition to reporting risk cases within the pharmacy, we are also involved in the review and planning of measures for all risk cases related to drug therapy within the hospital.

Diabetes Care Guidance Team

We support diabetic patients to proactively approach treatment and manage it themselves. By participating in conferences, exchanging information with other professionals, and accompanying patients on rounds, we strive to fully understand the treatment plan and the patient's condition so that we can support them throughout their treatment.

cardiac rehabilitation team

It explains in an easy-to-understand manner the purpose and precautions for use of cardiovascular drugs. We participate in conferences and strive to provide effective drug treatment while collaborating with other occupations.

heart failure team

For patients with end-stage heart failure, we consider not only the patient but also the surrounding environment such as their family, and consider a treatment plan for after discharge with a multidisciplinary team. Pharmacists propose drug therapies appropriate for patients and strive to ensure that treatment can be continued safely.

interstitial pneumonia support team

We support the treatment of patients with interstitial pneumonia through multidisciplinary collaboration. Pharmacists explain to patients and their families who are starting outpatient drug therapy such as antifibrotic drugs about precautions to take, side effects and countermeasures, and support the continuation of treatment while monitoring side effects.

Psychiatry Liaison Team

For inpatients with delirium, peripheral symptoms of dementia, and mental symptoms such as depression, we provide multidisciplinary support so that treatment can be continued smoothly through drug treatment and psychoeducation, etc., with an eye toward discharge from the hospital.

Dementia care team

Multidisciplinary support is provided to hospitalized patients who are difficult to care for due to dementia. Pharmacists suggest drug therapies that will help with care, such as polypharmacy, how to use sleeping pills to prevent delirium, and pain control.

Post-operative pain management (APS) team

We work in a multidisciplinary team with Anesthesiology and nurses to alleviate symptoms such as pain and nausea after surgery.

CAR-T Cell Therapy Team

We work with doctor, clinical laboratory technicians, clinical engineers, nurses, and administrative staff to provide CAR-T cell therapy, a new treatment for leukemia and lymphoma. In addition to handling cell preparation and freezing management of cell products, pharmacists also play the role of coordinator, sharing and coordinating information within the team, and securing production slots with manufacturers.

Fracture Liaison Service Team

In 2022, a new multidisciplinary team was established to treat patients with proximal femoral fractures, with Orthopedic Surgery surgeons at the center. As part of the team, pharmacists work with doctor to introduce osteoporosis medications to prevent secondary fractures. In addition, patients are often transferred to other hospitals for rehabilitation, and we share information so that patients can continue taking their medication at the new medical institution.

Hematopoietic Stem Cell Transplantation Team

We hold transplant conferences with the aim of early discharge of transplant patients through collaboration between doctor, nurses, physical therapists, Registered Dietitian, etc. Pharmacists share information to ensure that all medications, including anticancer drugs, immunosuppressants, antibiotics, and antivirals, can be continued safely and effectively.

Polypharmacy support

The more commonly used drugs, the more likely it is that side effects and other problems will occur. Pharmacists work with doctor and nurses to optimize the drugs that hospitalized patients regularly use.

Pharmacist education and clinical research

We have established a seamless educational system that includes everything from practical pharmacy training to postgraduate education for new staff and a pharmacist resident education program, and training for specialized pharmacists. Instructing trainees, pharmacist residents and second-year regular staff pharmacists act as preceptors to instruct students, while pharmacists with similar years of experience support the trainees as mentors, and a certified practical training instructor supervises and guides them in a "Yanegawara" educational system. By having pharmacist residents and staff pharmacists in charge of instructing trainees, we value an environment where all staff "learn and grow together."

Furthermore, we have established a system for mutual information exchange and guidance in education and research with the Kobe Gakuin University Graduate School of Pharmaceutical Sciences. We are engaged in research on the evaluation of task shift/share and digitalization, and research on support for drug blood concentration evaluation and optimal dosing plans based on pharmacokinetics/pharmacodynamics (PK/PD). By reflecting the research process in our work, we hope to improve the quality and safety of drug therapy.

Resident system

Overview 研修規程 研修プログラム 自己評価調査票 外部評価報告書

For those who wish to become a resident or staff member

Young staff interview

About the tour of the pharmacy department

The pharmacy department of our hospital holds tours for pharmacist residents and staff on the morning of the second Thursday of each month (online) and the morning of the third Thursday of each month (in-hospital format). We look forward to your participation.

Depending on the situation of the new coronavirus infection, we may not be able to meet your request for a visit-style tour. Please note.

Application method

Please be sure to fill in 1 to 5 below and apply by e-mail at least 14 days before the tour date.

  1. Name (furigana)
  2. sex
  3. University name, grade
  4. Desired schedule (please let us know up to your second choice)
  5. Preferred method of visit (visit or online)

Application destination

c_pharm-publicity@kcho.jp (The subject should be [Tour Application].)
If you have any other questions, please contact us at the number below.

Contact information

responsible person

Ryo Tamura, Public Relations and Visitors, Pharmacy Department
Tel. 078-302-4321 (representative)

For regional medical institutions

For insurance pharmacies

About inquiries about out-of-hospital prescriptions

For inquiries regarding out-of-hospital prescriptions,

  • For details of prescription, contact the doctor through the pharmacy department
  • For prescriptions such as insurance, please contact the accounting department (medical affairs section).

Please contact us. Since the prescribing doctor may be under examination, please contact us after summarizing your doubts.

About medication information sheet (tracing report)

At our hospital, we have prepared a medication information sheet (tracing report).
Information that is deemed desirable to be provided to the prescribing doctor, although the immediacy is low, is collected by the insurance pharmacy by fax (addressed to the pharmacy department), and information is transmitted to the doctor for information sharing. .

Please use the medication information provision form after confirming the operation of the attachment below.
Regarding outpatient cancer chemotherapy, please refer to the following "Drug Information Sheet for Outpatient Cancer Chemotherapy Please use from.

About the operation of the medication information provision form (tracing report)

PDF file "Medication Information Form (Tracing Report)" EXCELファイル「服薬情報提供書（トレーシングレポート）」

[July 2019 version]

“Cell-killing anti-cancer drug” drug information sheet (tracing report) “Molecular targeted drug ± cytotoxic anticancer drug” drug information provision form (tracing report) “Immune Checkpoint Inhibitor” Drug Information Sheet (Tracing Report)

[August 2023 version]

Fax address

(078) 302-5534 pharmacy department

About providing information to our hospital after changing to generic drugs

We will change the method of providing information from the conventional FAX to the following method.

  1. After changing to a generic drug, please give the patient an instruction manual or specify the details of the change in the medicine notebook.
  2. Please instruct the patient to show these to the doctor the next time he or she visits our hospital.

Newly Adopted and Deleted Drugs

List of drugs used (as of October 2024)

October 2, 2024: Newly adopted drugs and drugs that have been changed or deleted

Adopted chemicals
  • Phenol-zinc oxide liniment "Nikko"
  • Clopidogrel tablets 25mg "SANIK"
Introduction of generics
  • Repaglinide Tablets 0.25mg "SAWAI"
  • Repaglinide Tablets 0.5mg "SAWAI"
  • Letrozole Tablets 2.5mg "Sandoz"
Remove chemicals
  • Surepost Tablets 0.25mg
  • Surepost Tablets 0.5mg
  • Phenol-Zinc Oxide Liniment (Hachi)
  • Sennoside Granules 8%
  • Rabecure Pack 400 (for outpatient use only)
  • Rabefine Pack (for outpatient use only)
  • Lyquismia subcutaneous injection 300μg
  • Gascon Drops Oral Solution 2% 300mL

August 2, 2024: Newly adopted drugs and drugs that have been changed or deleted

Adopted chemicals
  • Torcap Tablets 160mg (for outpatient use only)
  • Torcap Tablets 200mg (for outpatient use only)
  • Bebespi Aerosphere 120 inhalations
Remove chemicals
  • Bevespi Aerosphere 28 inhalations

July 2, 2024: Newly adopted drugs and drugs that have been changed or deleted

Adopted chemicals
  • Canaglu OD Tablets 100mg
  • Manjaro Subcutaneous Injection 7.5mg Ateos (For outpatient use only)
  • Manjaro Subcutaneous Injection 10mg Ateos (For outpatient use only)
  • Manjaro Subcutaneous Injection 12.5mg Ateos (For outpatient use only)
  • Manjaro Subcutaneous Injection 15mg Ateos (For outpatient use only)
  • RINVOQ Tablets 7.5mg (for outpatient use only)
Remove chemicals
  • Canaglu Tablets 100mg

June 4, 2024: Alternative medicines for shipment adjustments, shortages, etc.

alternative medicine
  • Dipyridamole Tablets 25mg "Towa" (alternative to Persantin Tablets 25mg)
  • Valsartan OD Tablets 80mg "Towa" (alternative to Valsartan Tablets 80mg "Sandoz")

June 4, 2024: Newly adopted drugs and drugs that have been changed or deleted

Adopted chemicals
  • Fossebel Tablets 5mg
  • Fossebel Tablets 10mg
  • Itraconazole oral solution 1% "VTRS"
Introduction of generics
  • Zonisamide OD Tablets 25mg TRE "SMPP"
  • Zonisamide OD Tablets 50mg TRE "SMPP" (for outpatient use only)
Remove chemicals
  • Trereef OD Tablets 25mg
  • Itrizole oral solution 1%
  • Unifil LA Tablets 200mg
  • Detrusitol Capsules 2mg
  • Detrusitol Capsules 4mg (for outpatient use only)
  • Colantil blended granules

May 27, 2024: Orders for alternative drugs suspended due to resumption of shipments

Alternative drugs that will be suspended
  • Kracie Goreisan Extract Fine Granules 2.0g/package (substitute for Tsumura Goreisan Extract Granules (Medical Use) 2.5g/package)

May 2, 2024: Newly adopted drugs and drugs that have been changed or deleted

Adopted chemicals
  • Nerizona Ointment 0.1% 10g (for outpatient use only)
Remove chemicals
  • Nerizona Ointment 0.1% 5g (for outpatient use only)
  • Intelence Tablets 100mg

April 5, 2024: Alternative medicines for shipment adjustments, shortages, etc.

alternative medicine
  • Amantadine hydrochloride tablets 50 mg "SAWAI" (alternative to Symmetrel tablets 50 mg)
Introduction

The regimens published here were reviewed and approved by the Cancer Chemotherapy Committee of Kobe City Medical Center General Hospital. This document is provided for the purpose of proper administration management of patients undergoing cancer treatment at our hospital, and is not intended to be used for any other purpose. Dosage, dosing schedule, and supportive care may vary depending on the patient's condition.

Cancer chemotherapy regimen

Cancer chemotherapy regimen Lung cancer

Update date and time: September 9, 2024

P16-101 (With radiotherapy) PTX Weekly PDF
P16-101 (No cure) PTX Weekly PDF
P15-204 Every 3 weeks S1/CDDP PDF
A15-202 Abraxane (d1,8,15)/CBDCA triweekly PDF
A15-101 Abraxane weekly PDF
P15-404 ADOC PDF
B17-202 Afatinib daily/Bev triweekly PDF
A21-101 AMR (35) (d1-3) triweekly (NSCLC) PDF
A21-101 AMR (40) (d1-3) triweekly (SCLC) PDF
A19-302 Atezo/CBDCA(5)/ETP(100)(d1-3)q3w PDF
A19-302 Atezo/CBDCA/nabPTX(d1,8,15) q3w PDF
A19-304 Atezo/CDDP/PEM q3w PDF
A19-202 Atezo/PEM q3w maintenance therapy PDF
A19-303 Atezo/PEM/CBDCA q3w PDF
A18-102 Atezolizumab triweekly (NSCLC) PDF
A18-202 Atezolizumab/Bev q3w maintenance therapy PDF
A18-402 Atezolizumab/Bev/CBDCA/PTX q3w PDF
B15-102 Bev triweekly PDF
A15-303 Bev/Abraxane (d1,8,15)/CBDCA triweekly PDF
D16-202 Bev/DTX triweekly PDF
G15-202 Bev/GEM(d1,8) triweekly PDF
P15-203 Bev/PEM (500) triweekly PDF
P15-304 Bev/PEM/CBDCA triweekly PDF
P15-306 Bev/PEM/CDDP triweekly PDF
P16-202 Bev/PTX (d1,8,15) monthly PDF
P16-303 Bev/PTX(d1,8,15)/CBDCA monthly PDF
P16-303 Bev/PTX/CBDCA triweekly PDF
C19-101  CBDCA (30) daily + RT (NSCLC) PDF
C15-203 CBDCA(5)/ETP(80) (d1-3) triweekly PDF
P15-101 CDDP it PDF
P15-201 CDDP it/ADM it PDF
P15-205 CDDP(80)/ETP(100) (d1-3) triweekly PDF
P15-201 CDDP (d1-3)/ETP (d1-3) triweekly PDF
V15-403 CODE 1st week PDF
V15-202 CODE 2nd, 4th, 6th, 8th week PDF
A15-303 CODE 3rd, 5th, 7th, 9th week PDF
CPT16-101 CPT-11 (100) weekly (lung cancer) PDF
CPT15-202 CPT-11(d1,8,15)/CBDCA monthly PDF
CPT15-204 CPT-11 (d1,8,15)/CDDP monthly (NSCLC) PDF
CPT15-204 CPT-11 (d1,8,15)/CDDP monthly (SCLC) PDF
D16-101 DTX (60) triweekly (lung cancer) PDF
D16-202 DTX(d1,8)/CDDP(d1,8) monthly PDF
D16-202 DTX/CBDCA triweekly (lung cancer) PDF
D16-203 DTX/CDDP triweekly PDF
D20-302 Durva(BW≦30)/CBDCA/ETP(d1-3)q3w PDF
D20-303 Durva(BW≦30)/CDDP/ETP(d1-3)q3w PDF
D23-101 Durva(Treme/Durva)q4w maintenance first time/third time~ PDF
D20-302 Durva/CBDCA/ETP(d1-3)q3w PDF
D20-303 Durva/CDDP/ETP(d1-3)q3w PDF
D23-201 Durva/PEM(Treme/Durva)q4w maintenance first/third time~ PDF
D23-101 Durvalumab after CRT q4w(BW>30kg)(NSCLC) PDF
D23-101 Durvalumab after CRT q4w(BW≦30kg)(NSCLC) PDF
D20-101 Durvalumab (BW ≤ 30) maintenance q4w (ES-SCLC) PDF
D20-101 Durvalumab maintenance q4w (ES-SCLC) PDF
B15-202 Erlotinib daily/Bev triweekly PDF
E15-102 ETP (d1-3) triweekly PDF
B17-202 Gefitinib daily/Bev triweekly PDF
G15-101 GEM(d1,8) triweekly (lung cancer) PDF
G15-202 GEM(d1,8)/CBDCA(AUC=4-6) triweekly PDF
G15-204 GEM(d1,8)/CDDP triweekly PDF
G15-101 GEM (d1,8,15) monthly (lung cancer) PDF
G19-304 Neci(d1,8)/GEM(d1,8)/CDDP triweekly PDF
N19-101 Necitumumab(d1,8) triweekly maintenance therapy PDF
N23-301 Nivo/GEM(d1,8)/CDDP q3w (preoperatively) (squamous cell carcinoma) PDF
N20-203 Nivo(d1,22)/Ipi(d1) q6w PDF
N20-405 Nivo/Ipi/PEM/CBDCA q3w (1c eyes) PDF
N20-405 Nivo/Ipi/PEM/CDDP q3w (1c eye) PDF
N20-404 Nivo/Ipi/PTX/CBDCA q3w (1c eye) PDF
N20-304 Nivo/PEM/CBDCA q3w (2c eyes) PDF
N23-301 Nivo/PEM/CDDP triweekly (preoperatively) (non-squamous cell carcinoma) PDF
N20-304 Nivo/PEM/CDDP q3w (2c eyes) PDF
N20-303 Nivo/PTX/CBDCA q3w (2c eyes) PDF
N23-301 Nivo/PTX/CBDCA triweekly (preoperatively) PDF
N18-102 Nivolumab biweekly (NSCLC) PDF
N20-102 Nivolumab (480mg/b) q4w (NSCLC) PDF
O24-201 Osimertinib+PEM triweekly (maintained) PDF
O24-301 Osimertinib+PEM/CBDCA triweekly PDF
O24-301 Osimertinib+PEM/CDDP triweekly PDF
P15-102 PEM (500) triweekly PDF
P15-203 PEM/CBDCA triweekly PDF
P15-206 PEM/CDDP triweekly PDF
P17-102 Pembrolizumab triweekly (NSCLC) PDF
P20-101 Pembrolizumab (400mg/b) q6w (NSCLC) PDF
P18-302 Pembrolizumab/CBDCA/nabPTX(d1,8,15)q3w PDF
P18-303 Pembrolizumab/CBDCA/PEMq3w1-4c PDF
P18-302 Pembrolizumab/CBDCA/PTX triweekly PDF
P18-304 Pembrolizumab/CDDP/PEMq3w1-4c PDF
P18-202 Pembrolizumab/PEM q3w maintenance therapy PDF
P16-202 PTX(70)(d1,8,15)/CBDCA(6) monthly PDF
P16-202 PTX/CBDCA triweekly (lung cancer) PDF
P16-201 PTX/CBDCA Weekly PDF
R18-102 Ram triweekly PDF
D16-202 Ram/DTX triweekly PDF
E20-201 Ram/Erlotinib (d1-14) biweekly PDF
B17-202 S1(d1-14)/Bev triweekly (lung cancer) PDF
C15-202 S1 (d1-14)/CBDCA triweekly PDF
T23-101 T-DXd triweekly (lung cancer) PDF
T15-101 Topotecan(d1-5) triweekly PDF
T23-401 Treme/Durva/nabPTX(d1,8,15)･CBDCA q3w 1-4c PDF
T23-401 Treme/Durva/PEM/CBDCA triweekly 1-4c PDF
T23-401 Treme/Durva/PEM/CDDP triweekly 1-4c PDF
T23-201 Treme/Durva q4w maintenance 2nd time PDF
T23-301 Treme/Durva/PEM q4w 2nd maintenance PDF
V15-101 VNR weekly (lung cancer) PDF
V15-202 VNR(d1,8)/CBDCA triweekly PDF
V15-204 VNR(d1,8)/CDDP triweekly PDF
V15-201 VNR(d1,8)/CDDP(d1,8) triweekly PDF
P15-204 Radiation every 3 weeks S1/CDDP PDF
V15-202 Radiation VNR (d1,8)/CDDP (d1,8) triweekly PDF

Cancer chemotherapy regimen breast cancer

Update date and time: March 12, 2024

A15-101 Abraxane triweekly PDF
A15-201 AC (breast cancer) PDF
A19-201 Atezo(d1,15)/nabPTX(d1,8,15) monthly PDF
F15-201 CMF (breast cancer) PDF
CPT16-101 CPT-11 weekly (breast cancer) PDF
A15-202 dose-dense AC (breast cancer) PDF
E22-201 dose-dense EC (breast cancer) PDF
D16-101 DTX triweekly (breast cancer) PDF
D16-201 DTX/CPA triweekly (breast cancer) PDF
E15-202 EC triweekly (breast cancer) PDF
E15-101 Eribulin (d1,8) triweekly PDF
F15-301 FEC (breast cancer) PDF
G15-101 GEM (d1,8) triweekly (breast cancer) PDF
F15-301 iv CMF (breast cancer) PDF
P22-301 Pembro/ADM(60)/CPA(600) triweekly PDF
P22-301 Pembro/EPI(90)/CPA(600) triweekly PDF
P22-301 Pembro/wPTX(80)/CBDCA (AUC5) triweekly PDF
P21-301 Pembro/GEM/CBDCA (AUC=2) triweekly PDF
P22-101 Pembrolizumab (200) q3w (breast cancer) PDF
P22-101 Pembrolizumab (400) q6w (breast cancer) PDF
P21-201 Pembrolizumab/nab-PTX(d1,8) triweekly PDF
P21-201 Pembrolizumab/PTX(d1,8) triweekly PDF
P18-201 PER/Tmab triweekly (first course) PDF
P18-201 PER/Tmab triweekly (after the 2nd course) PDF
P18-301 PER/Tmab/DTX triweekly (first course) PDF
P18-301 PER/Tmab/DTX triweekly (after 2nd course) PDF
P19-401 PER/Tmab/DTX/CBDCA triweekly (first course) PDF
P19-401 PER/Tmab/DTX/CBDCA triweekly (after the 2nd course) PDF
P18-301 PER/Tmab/PTX triweekly (first course) PDF
P18-301 PER/Tmab/PTX triweekly (after 2nd course) PDF
P23-201 PHESGO triweekly (1st course) PDF
P23-201 PHESGO triweekly (2nd course onwards) PDF
P23-301 PHESGO/DTX triweekly (1st course) PDF
P23-301 PHESGO/DTX triweekly (2nd course onwards) PDF
P23-401 PHESGO/DTX/CBDCA triweekly (1st course) PDF
P23-401 PHESGO/DTX/CBDCA triweekly (2nd course onwards) PDF
P23-301 PHESGO/nabPTX triweekly (1st course) PDF
P23-301 PHESGO/nabPTX triweekly (2nd course onwards) PDF
P23-301 PHESGO/PTX triweekly (1st course) PDF
P23-301 PHESGO/PTX triweekly (2nd course onwards) PDF
P23-302 PHESGO/VNR(d1,8) triweekly (1st course) PDF
P23-302 PHESGO/VNR(d1,8) triweekly (2nd course onwards) PDF
P16-101 PTX weekly (breast cancer) PDF
P16-201 PTX(d1,8,15)/BV(d1,15) monthly PDF
T15-101 T-DM1 triweekly PDF
T20-101 T-DXd triweekly PDF
T20-101 Tmab triweekly (first time) PDF
T20-101 Tmab triweekly (second time onwards) PDF
T20-101 Tmab weekly (1st time) PDF
T20-101 Tmab weekly (after the second time) PDF
T20-201 Tmab/Abraxane triweekly (1st time) PDF
T20-201 Tmab/Abraxane triweekly (after the second time) PDF
T20-201 Tmab/CPT-11 weekly (1st time) PDF
T20-201 Tmab/CPT-11 weekly (after the second time) PDF
T20-201 Tmab/DTX triweekly (1st time) PDF
T20-201 Tmab/DTX triweekly (after the second time) PDF
T20-301 Tmab/DTX/CBDCA triweekly (first course) PDF
T20-301 Tmab/DTX/CBDCA triweekly (after the 2nd course) PDF
T20-301 Tmab/DTX/CPA triweekly (first course) PDF
T20-301 Tmab/DTX/CPA triweekly (after the 2nd course) PDF
T20-201 Tmab/Eribulin (d1,8) triweekly (first course) PDF
T20-201 Tmab/Eribulin (d1,8) triweekly (after the 2nd course) PDF
T20-201 Tmab/PTX weekly (1st time) PDF
T20-201 Tmab/PTX weekly (after the second time) PDF
T20-301 Tmab/PTX(d1, 8)/GEM(d1, 8) triweekly (first course) PDF
T20-301 Tmab/PTX(d1, 8)/GEM(d1, 8) triweekly (after the 2nd course) PDF
T20-301 Tmab/PTX/CBDCA triweekly (first course) PDF
T20-301 Tmab/PTX/CBDCA triweekly (after the 2nd course) PDF
T20-201 Tmab/VNR (d1, 8) triweekly (first course) PDF
T20-201 Tmab/VNR (d1, 8) triweekly (after the 2nd course) PDF
V15-101 VNR weekly (breast cancer) PDF
T20-201 weekly Tmab/Abraxane (after the second time) PDF
     

Cancer chemotherapy regimen gastric cancer

Update date and time: September 9, 2024

P15-203 Every 5 weeks S1/CDDP PDF
A17-101  Abraxane weekly (stomach cancer) PDF
CPT15-102 CPT-11 biweekly (gastric cancer) PDF
CPT15-202 CPT-11(d1, 15)/CDDP monthly (gastric cancer) PDF
CPT15-202 CPT-11/CDDP biweekly PDF
D16-101  DTX weekly (stomach cancer) PDF
F17-203 FOLFOX6 (gastric cancer) PDF
F21-201 5-FU/l-LV+PTX monthly PDF
O15-202 G-SOX (100mg/m2) triweekly PDF
O15-202 G-SOX (130mg/m2) triweekly PDF
O15-202 G-XELOX triweekly PDF
H18-201 HER/CAP (d1-14) triweekly (1st time) PDF
H18-201 HER/CAP (d1-14) triweekly (after the second time) PDF
O18-301 HER/G-SOX triweekly (first course) PDF
O18-301 HER/G-SOX triweekly (after 2nd course) PDF
O18-301 HER/XELOX triweekly (first course) PDF
O18-301 HER/XELOX triweekly (after the 2nd course) PDF
H18-302 HER/XP (first time) PDF
H18-302 HER/XP (2nd time onwards) PDF
T20-403 mFOLFOX6+Tmab biweekly (1c eye) PDF
T20-403 mFOLFOX6+Tmab biweekly (after 2c) PDF
P18-203 nabPTX(d1,8,15)/Ram(d1,15) monthly PDF
N21-303 Nivo/SOX triweekly PDF
N21-303 Nivo/XELOX triweekly PDF
N21-303 Nivo+mFOLFOX6 biweekly PDF
N18-102 Nivolumab biweekly (gastric cancer) PDF
N20-102 Nivolumab (480mg/b) q4w (gastric cancer) PDF
P16-101 PTX weekly (gastric cancer) PDF
R16-202 Ram(d1,15)/PTX(d1,8,15) monthly PDF
R21-202 Ram/CPT-11 biweekly PDF
R15-101 Ramucirumab biweekly PDF
D16-201 S1(d1-14)/DTX triweekly PDF
T20-102 T-DXd triweekly (gastric cancer) PDF
T20-201 Tmab/CAP (d1-14) triweekly (first time) PDF
T20-201 Tmab/CAP (d1-14) triweekly (after 2nd time) PDF
O20-303 Tmab/G-SOX triweekly (first course) PDF
O20-303 Tmab/G-SOX triweekly (after 2nd course) PDF
P18-305 Tmab/SP (first course) PDF
P18-305 Tmab/SP (after 2nd course) PDF
O20-303 Tmab/XELOX triweekly (first course) PDF
O20-303 Tmab/XELOX triweekly (after 2nd course) PDF
T20-304 Tmab/XP (first time) PDF
T20-304 Tmab/XP (after the second time) PDF
Z24-303 Zolbe+CAPOX triweekly 2nd course onwards PDF
Z24-301 Zolbe(d1)+CAPOX(d2) triweekly 2nd course onwards PDF
Z24-403 Zolbe+mFOLFOX6 biweekly 2nd course onwards PDF
Z24-401 Zolbe(d1)+mFOLFOX6(d2) biweekly 2nd course onwards PDF

Cancer chemotherapy regimen Esophageal cancer

Last updated: April 4, 2024

F16-204 CDGP/5FU (96 hours) monthly (infuser) PDF
F16-303 DCF monthly (Infuser) PDF
F21-303 DCF monthly (infuser) (with line keep) PDF
F22-301 DCF(70-70-3750) triweekly (Tunai) PDF
D16-101 DTX triweekly (esophageal cancer) PDF
P21-201 FP (1000/75) (5-FU: 96 hours, infuser) monthly PDF
P21-201 FP (1000/75) (5-FU: 96 hours, infusion pump) monthly PDF
F17-202 FP (70-700) radiation PDF
F17-202 high dose FP PDF
F15-203 high dose FP (5-FU: 120 hours, infuser) PDF
F15-203 high dose FP (5-FU: 96 hours, infuser) monthly PDF
N22-201 Nivo(d1,22)/Ipi(d1) q6w (esophageal cancer) PDF
N22-301 Nivo(day1,15)/FP monthly (esophageal cancer) PDF
N20-102 Nivolumab biweekly (esophageal cancer) PDF
N20-102 Nivolumab (480mg/b) q4w (esophageal cancer) PDF
P21-101 Pembrolizumab triweekly (esophageal cancer) PDF
P21-101 Pembrolizumab (400mg/b) q6w (esophageal cancer) PDF
P21-301 Pembrolizumab/FP triweekly (esophageal cancer) PDF
P16-101 PTX weekly (esophageal cancer) PDF

Cancer chemotherapy regimen colon cancer

Last updated: April 4, 2024

F18-302 Aflibercept/FOLFIRI biweekly PDF
F17-305 Bev(10mg/kg)/FOLFOX6 biweekly PDF
F17-303 Bev(5mg/kg)/FOLFIRI biweekly PDF
F17-305 Bev(5mg/kg)/FOLFOX6 biweekly PDF
CPT15-303 Bev(5mg/kg)/IRIS PDF
B15-202 Bev(d1, 15) /TAS-102(d1-5, 8-12) monthly PDF
C15-203 Bev/Cape(d1-14) triweekly PDF
O17-403 Bev/FOLFOXIRI PDF
O15-303 Bev/SOX triweekly PDF
O15-303 Bev/XELOX triweekly PDF
Cm15-101 Cmab weekly (first time) PDF
Cm15-101 Cmab weekly (after the second time) PDF
C15-204 Cmab weekly/CPT-11 biweekly (first course) PDF
C15-204 Cmab weekly/CPT-11 biweekly (after the 2nd course) PDF
F17-303 Cmab(d1, 8)/FOLFIRI (first course) PDF
F17-303 Cmab(d1, 8)/FOLFIRI (after the 2nd course) PDF
F17-303 Cmab(d1, 8)/FOLFOX6 (first course) PDF
F17-303 Cmab(d1, 8)/FOLFOX6 (after the 2nd course) PDF
C21-301 C-mab+encorafenib+binimetinib (first time) PDF
C21-301 C-mab+encorafenib+binimetinib (2nd time onwards) PDF
CPT15-102 CPT-11 biweekly (colorectal cancer) PDF
F17-202 FOLFIRI PDF
F17-202 FOLFOX6 PDF
O17-302 FOLFOXIRI PDF
N20-102 Nivo (480mg, Nivo/Ipi maintenance q4w, (MSI-H colorectal) PDF
N20-102 Nivo(Nivo/Ipi maintenance q2w(MSI-High colon/rectum) PDF
N20-203 Nivo/Ipi triweekly (MSI-High colorectal cancer) PDF
N20-102 Nivolumab q2w (MSI-High/Colorectal cancer) PDF
Pm16-101 Pmab biweekly PDF
Pm15-201 Pmab/CPT-11 biweekly PDF
F17-302 Pmab/FOLFIRI biweekly PDF
F17-302 Pmab/FOLFOX6 biweekly PDF
F17-303 Ram/FOLFIRI biweekly PDF
B15-202 S1(d1-28) / Bev(d1,15,29) every 6 weeks PDF
B17-303 SIRB triweekly PDF
O15-202 SOX PDF
F19-101 WHF therapy ia (infuser pump) weekly PDF
CPT18-303 XELIRI + Bev triweekly PDF
O15-202 XELOX PDF

Cancer chemotherapy regimen Bile/liver/pancreatic cancer

Last updated: June 12, 2024

A20-201 Atezolizumab/Bev q3w (hepatocellular carcinoma) PDF
D23-301 Durva(d1)/GC(d1,8) triweekly (BW＞30kg) PDF
D23-301 Durva(d1)/GC(d1,8) triweekly (BW≦30kg) PDF
D23-101 Durva (Treme/Durva) 2nd course or later (BW＞30kg)q4w PDF
D23-101 Durva (Treme/Durva) 2nd course or later (BW≦30kg)q4w PDF
D23-101 Durvalumab maintenance monthly (BW＞30kg) (Biliary tract cancer) PDF
D23-101 Durvalumab maintenance monthly (BW≦30kg) (Biliary tract cancer) PDF
F17-302 FOLFIRINOX PDF
G15-101 GEM biweekly (pancreatic cancer) PDF
G15-101 GEM (d1,8) triweekly (biliary tract cancer) PDF
G15-101 GEM(d1,8) triweekly (pancreatic cancer) PDF
G15-201 GEM(d1,8)/CDDP(d1,8) triweekly PDF
G20-201 GEM (d1,8) + S-1 (d1-14) triweekly (pancreatic cancer) PDF
G15-101 GEM (d1,8,15) monthly (biliary tract cancer) PDF
G15-101 GEM (d1,8,15) monthly (pancreatic cancer) PDF
F17-303 mFOLFIRINOX PDF
G15-204 nabPTX(d1,8,15)/GEM(d1,8,15) PDF
I20-202 nal-IRI/5-FU/l-LV biweekly PDF
P24-301 Pembro(d1)/GC(d1,8) triweekly PDF
P24-301 Pembro(d1)/GC(d1,8,22,29) q6w PDF
P24-201 Pembro(d1)/GEM(d1,8) q3w maintenance (biliary tract cancer) PDF
P24-201 Pembro(d1)/GEM(d1,8,22,29)q6w maintenance (biliary tract cancer) PDF
T23-201 Tremelimumab/Durva 1st course (BW＞30kg)monthly PDF
T23-201 Tremelimumab/Durva 1st course (BW≦30kg)monthly PDF
R19-102 Ram biweekly (hepatocellular carcinoma) PDF

Cancer chemotherapy regimen Gynecologic cancer

Update date and time: November 24, 2023

A15-101 ACTD biweekly PDF
A15-203 ADM/CDDP triweekly PDF
B15-305 BEP therapy (d1-5,9,16) (ovarian germ cell tumor) PDF
B20-302 Bev biweekly/CBDCA/PLD monthly PDF
B21-202 Bev biweekly/PLD monthly PDF
B15-102 Bev triweekly (gynecologic cancer) PDF
B15-202 Bev triweekly/PLD monthly 1st course PDF
B15-202 Bev triweekly/PLD monthly 2nd course PDF
B15-202 Bev triweekly/PLD monthly 3rd course PDF
B16-203 Bev triweekly/PTX weekly Course 1 PDF
B16-203 Bev triweekly/PTX weekly 2nd course PDF
B16-203 Bev triweekly/PTX weekly 3rd course PDF
D19-302 Bev/DTX/CBDCA triweekly (ovarian cancer) PDF
B17-202 Bev/GEM (d1,8) triweekly PDF
G15-302 Bev/GEM(d1,8)/CBDCA tri (gynecologic cancer) PDF
B22-202 Bev/Olaparib triweekly (ovarian cancer) PDF
P16-302 Bev/PTX/CBDCA triweekly (cervical cancer) PDF
P16-302 Bev/PTX/CBDCA triweekly (ovarian cancer) PDF
B18-302 Bev/PTX/topotecan(d1-3) triweekly PDF
B15-202 Bev/Topotecan(d1-5) triweekly PDF
C15-101 CBDCA weekly (gynecologic cancer) PDF
P15-102 CDDP weekly (for CCRT) PDF
C15-101 CDGP monthly PDF
C23-101 Cemiplimab triweekly PDF
CPT15-101 CPT-11 weekly (gynecologic cancer) PDF
CPT15-201 CPT-11(d1,8)/CDGP monthly PDF
C15-203 CPT-11(d1,8,15)/CDDPmonthly (gynecologic cancer) PDF
CPT15-202 CPT-11(d1,8,15)/CDGP monthly PDF
P16-202 divided weekly TC (AUC=2) PDF
P16-202 dose-dense TC PDF
D16-101 DTX triweekly (gynecologic cancer) PDF
D16-201 DTX (d8)/GEM (d1,8) triweekly (gynecologic cancer) PDF
D16-201 DTX/CBDCA triweekly (gynecologic cancer) PDF
M15-501 EMA/CO biweekly PDF
F17-201 FA biweekly PDF
G15-201 GEM(d1,8)/CBDCA(AUC=4) triweekly PDF
G15-101 GEM (d1,8,15) monthly (ovarian cancer) PDF
I18-101 IFM triweekly PDF
I18-201 IFM/PTX triweekly PDF
M14-101 MTX (d1-5) im biweekly (trophoblastic disease) PDF
M14-101 MTX im weekly (ectopic pregnancy) PDF
N15-101 Nogitecan(d1-5) triweekly PDF
A15-101 PLD monthly (90mg/body or less) PDF
A15-101 PLD monthly (90mg/body or more) PDF
P22-201 Pembro/Bev triweekly maintenance therapy PDF
P22-401 Pembro/Bev/PTX/CBDCA triweekly PDF
P22-401 Pembro/Bev/PTX/CDDP triweekly PDF
P21-201 Pembro/Lenvatinib q3week (uterine cancer) PDF
P21-201 Pembro/Lenvatinib q6week (uterine cancer) PDF
P22-301 Pembro/PTX/CBDCA triweekly PDF
P22-301 Pembro/PTX/CDDP triweekly PDF
P22-101 Pembrolizumab triweekly maintenance therapy (cervical cancer) PDF
A15-201 PLD/CBDCA monthly PDF
P16-102 PTX weekly (gynecologic cancer) PDF
P16-202 PTX/CBDCA triweekly (gynecologic cancer) PDF
P16-203 PTX/CDDP triweekly (gynecologic cancer) PDF
P16-303 TP/TE PDF
P16-202 weekly TC (AUC=6) PDF

Cancer chemotherapy regimen Urologic/germinoma

Last updated: April 4, 2024

A20-201 Axitinib daily/Avelumab biweekly PDF
P19-201 Axitinib daily/pembrolizumab triweekly PDF
P20-201 Axitinib daily/pembrolizumab (400mg/b) q6w PDF
N24-201 Cabozantinib daily/Nivolumab biweekly PDF
N24-201 Cabozantinib daily/Nivolumab(480mg)monthly PDF
D16-201 DTX(d8)/GEM(d1,8) tri (urothelial carcinoma) PDF
E24-201 Enfortumab vedotin(d1,8)+Pembrolizumab q3w PDF
E21-101 Enfortumab vedotin q4week (urothelial carcinoma) PDF
G15-202 GC therapy (d1,8,15) PDF
P15-203 GC therapy (d2) PDF
G15-202 GEM (d1,8,15)/CBDCA (d1) monthly PDF
C14-202 GEM(d1,8,15)/CBDCA(d2)monthly PDF
P24-201 Lenvatinib daily/Pembrolizumab triweekly PDF
P24-201 Lenvatinib daily/Pembrolizumab(400mg) q6w PDF
E15-402 mitotane daily / EDP monthly PDF
M15-403 M-VAC therapy (afternoon start) PDF
N18-202 Nivo (Nivo/Ipi maintenance therapy biweekly (renal cell carcinoma) PDF
N20-102 Nivo (Nivo/Ipi maintenance therapy 480mg/b) q4w (renal cell carcinoma) PDF
N18-203 Nivo/Ipi triweekly (renal cell carcinoma) PDF
N18-102 Nivolumab biweekly (renal cell carcinoma) PDF
N20-102 Nivolumab (480mg/b) q4w (renal cell carcinoma) PDF
P17-101 Pembrolizumab tri (urothelial carcinoma) PDF
P20-101 Pembrolizumab (400mg/b) q6w (urothelial carcinoma) PDF
C15-201 PSL daily/Cabazitaxel triweekly PDF
D18-201 PSL(d1-7)/DTX triweekly_(morning start) PDF
P16-202 PTX/CBDCA triweekly (urothelial carcinoma) PDF
N24-101 Postoperative adj Nivolumab biweekly (urothelial carcinoma) PDF
N24-101 Postoperative adj Nivolumab monthly (urothelial cancer) PDF
P24-101 Postoperative adj Pembrolizumab triweekly (kidney cancer) PDF
P24-101 Postoperative adj Pembrolizumab (400mg) Q6W (kidney cancer) PDF

Cancer chemotherapy regimen Hematopoietic malignancies

Update date and time: September 9, 2024

B18-401 ABVD (outpatient) PDF
A20-301 A-CHP PDF
A15-101 AzaC (d1-7)_monthly (outpatient) PDF
A19-101 AzaC subcutaneous injection (d1-7)_monthly (outpatient) PDF
B22-101 Blinatumomab for home pump 28μg/d 72hr with Dex PDF
B22-101 Blinatumomab for home pump 28μg/d 96hr with Dex PDF
B22-101 Blinatumomab for home pump 28μg/d 72hr No Dex PDF
B22-101 Blinatumomab for home pump 28μg/d 96hr No Dex PDF
B22-101 Blinatumomab for home pump 15μg/㎡ 72h with Dex PDF
B22-101 Blinatumomab for home pump 15μg/㎡ 96h with Dex PDF
B22-101 Blinatumomab for home pump 15μg/㎡ 72h No Dex PDF 
B22-101 Blinatumomab for home pump 15μg/㎡ 96h No Dex PDF
B22-101 Blinatumomab for home pump 9μg/d 72hr with Dex PDF
B22-101 Blinatumomab for home pump 9μg/d 96hr with Dex PDF
B22-101 Blinatumomab for home pump 9μg/d 72hr No Dex PDF
B22-101 Blinatumomab for home pump 9μg/d 96hr No Dex PDF
B22-101 Blinatumomab for home pump 5μg/㎡ 72hr with Dex PDF
B22-101 Blinatumomab for home pump 5μg/㎡ 96hr with Dex PDF
B22-101 Blinatumomab for home pump 5μg/㎡ 72hr No Dex PDF
B22-101 Blinatumomab for home pump 5μg/㎡ 96hr No Dex PDF
B17-101 Brentuximab triweekly (BW>87) PDF
B17-101 Brentuximab triweekly (BW≤87) PDF
A15-301 CHOP (Outpatient) PDF
CPT15-101 CPT-11(d1-3) weekly PDF
D23-101 Darinaparsin triweekly PDF
D21-203 DBdsc therapy cycle 1-3 PDF
D21-203 DBdsc therapy cycles 4-8 PDF
D21-203 DBdsc therapy cycle 9 and beyond PDF
D18-202 DBd therapy triweekly cycle 1 PDF
D18-202 DBd therapy triweekly cycle 2-3 PDF
D18-202 DBd therapy triweekly cycles 4-8 PDF
D17-201 DBd therapy monthly Cycle 9 or later PDF
D22-301 DCyBorD Therapy (iv) Cycle 1-2 PDF
D22-301 DCyBorD therapy (iv) cycles 3-6 PDF
D22-301 DCyBorD therapy (po) cycle 1-2 PDF
D22-301 DCyBorD therapy (po) cycles 3-6 PDF
D22-101 DCyBorD therapy cycle 7 and beyond PDF
D21-203 DKdsc therapy Cycle 1 PDF
D21-203 DKdsc therapy Cycle 2 PDF
D21-203 DKdsc therapy cycle 3-6 PDF
D21-203 DKdsc therapy Cycle 7 or later PDF
D20-201 DKd therapy monthly Cycle 1 PDF
D20-201 DKd therapy monthly Cycle 2 PDF
D20-201 DKd therapy monthly cycle 3-6 PDF
D20-201 DKd therapy monthly Cycle 7- PDF
D21-203 DKdsc therapy (*K once a week) Cycle 1 PDF
D21-203 DKdsc therapy (*K once a week) Cycle 2 PDF
D21-203 DKdsc therapy (*K once a week) Cycles 3-6 PDF
D21-203 DKdsc therapy (*K once a week) from cycle 7 onwards PDF
D17-201 DLd therapy monthly Cycle 1 PDF
D17-201 DLd therapy monthly Cycle 2 PDF
D17-201 DLd therapy monthly cycle 3-6 PDF
D17-201  DLd therapy monthly Cycle 7 or later PDF
D21-203 DLdsc therapy cycle 1-2 PDF
D21-203 DLdsc therapy cycle 3-6 PDF
D21-203 DLdsc therapy cycle 7 and beyond PDF
D23-201 DPdsc therapy cycle 1-2 PDF
D23-201 DPdsc therapy cycle 3-6 PDF
D23-201 DPdsc therapy Cycle 7 or later PDF
D20-401 D-VMP Therapy Cycle 1 PDF
D20-401 D-VMP Therapy Cycle 2-9 PDF
D20-401 D-VMP therapy Cycle 10 and beyond PDF
D21-403 D-VMPsc therapy cycle 1 PDF
D21-403 D-VMPsc therapy cycles 2-9 PDF
D21-403 D-VMPsc therapy cycle 10 and beyond PDF
E19-301 EPd therapy (1st-2nd course) PDF
E19-301 EPd therapy (after the 3rd course) PDF
E16-301 ERd therapy (1st course) PDF
E16-301 ERd therapy (2nd course) PDF
E16-301 ERd therapy (after the 3rd course) PDF
G15-301 GCOP (1000) (outpatient) PDF
G15-301 GCOP (750) (outpatient) PDF
G15-301 GCOP (875) (outpatient) PDF
G15-101 GDP_Over 70 (outpatient) PDF
I18-101 Inotuzumab ozogamicin (until remission) PDF
I18-101 Inotuzumab ozogamicin (post-remission) PDF
I20-302 IPd therapy (BW≤85) (1st course) PDF
I20-302 IPd therapy (BW ≤ 85) (after the 2nd course) PDF
I20-302 IPd therapy (BW86-100) (1st course) PDF
I20-302 IPd therapy (BW86-100) (after 2nd course) PDF
I22-201 Isad therapy monthly cycle 1 (BW ≤ 85) PDF
I22-201 Isad therapy monthly cycle 1 (BW86-100) PDF
I22-201 Isad therapy monthly cycle 2 or later (BW ≤ 85) PDF
I22-201 Isad therapy monthly cycle 2 or later (BW86-100) PDF
I22-301 IsaKd therapy monthly cycle 1 (BW ≤ 85) PDF
I22-301 IsaKd therapy monthly cycle 1 (BW86-100) PDF
I22-301 IsaKd therapy monthly Cycle 2 or later (BW ≤ 85) PDF
I22-301 IsaKd therapy monthly Cycle 2 or later (BW86-100) PDF
C19-201 Kd weekly (first course) PDF
C19-201 Kd weekly (after the 2nd course) PDF
C18-201 Kd therapy (1st course) PDF
C18-201 Kd therapy (after the 2nd course) PDF
C18-301 KRd therapy (1st course) PDF
C18-301 KRd therapy (2nd to 12th course) PDF
C18-301 KRd therapy (13th to 18th course) PDF
M15-101 Mogamulizumab weekly PDF
N18-102 Nivolumab biweekly (Hodgkin's lymphoma) PDF
O18-204 Obi-Bendamustine C2-6 PDF
O18-402 Obi-CHOP C2-6 PDF
O18-102 Obi-CHOP C7-8 PDF
O18-302 Obi-CVP C2-8 PDF
O18-102 Obinutuzumab (maintenance/monotherapy) PDF
O24-201 Obi(d1,2,8,15)-Acalabrutinib q4w C2 PDF
O24-201 Obi-Acalabrutinib q4w C3-7 PDF
A17-101 PLD biweekly PDF
P24-301 Pola-BR (BW＜42kg) q3w C2-6 (Outpatient) PDF
P24-301 Pola-BR (BW≧42kg) q3w C2-6 (outpatient) PDF
P24-401 Pola-R-CHP (BW＜42kg) triweekly C2-6 (outpatient) PDF
P24-401 Pola-R-CHP (BW≧42kg) triweekly C2-6 (outpatient) PDF
P22-101 Pola-R-CHP triweekly C7-8 (outpatient) PDF
M15-401 POMP therapy (first year) PDF
P18-103 Weekly Pralatrexate PDF
R20-201 R2 (cycle 1) PDF
R20-201 R2 (cycle 2-5) PDF
R19-203 R-Bendamustine (Outpatient) PDF
R14-402 R-THPCOP (outpatient) PDF
C19-301 RCD (CPA div) PDF
R19-301 RCD (CPA po) PDF
R19-401 R-CHOP (Outpatient) PDF
R19-301 R-GCD (outpatient) triweekly PDF
R20-401 R-GCOP (1000) (outpatient) PDF
R20-401 R-GCOP (750) (outpatient) PDF
R19-201 R-GDP 70+ (outpatient) triweekly PDF
R19-302 R-GDP (Foreign) triweekly PDF
R19-101 Rituximab (outpatient) PDF
R19-401 R-mini CHOP (Outpatient) PDF
C23-201 VEN＋low dose Ara-C subcutaneous injection (d1-10) monthly PDF
A15-102 Arsenite after remission PDF
A15-102 Arsenite Remission induction PDF

Cancer chemotherapy regimen Head and neck cancer

Last updated: April 4, 2024

C15-203 CBDCA/5-FU triweekly PDF
P18-102 CDDP(40) + RT weekly PDF
Cm15-101 Cmab weekly with radiation (first time) PDF
Cm15-101 Cmab weekly combined with radiation (2nd time onwards) PDF
C15-304 Cmab(d1,8,15)/CBDCA･5-FU triweekly(initial course) PDF
C15-304 Cmab(d1,8,15)/CBDCA/5-FU triweekly(2nd and subsequent doses) PDF
C15-305 Cmab/FP triweekly (first course) PDF
C15-305 Cmab/FP triweekly (2nd course onwards) PDF
C16-201 Cmab/PTX weekly (1st course) PDF
C16-201 Cmab/PTX weekly (after 2nd course) PDF
F15-205 FP (70-700) (5-FU, 96 hours, infuser) (head and neck)) PDF
N18-102 Nivolumab biweekly (head and neck cancer) PDF
N20-102 Nivolumab (480mg/b) q4w (head and neck cancer) PDF
P19-101 Pembrolizumab triweekly (head and neck cancer) PDF
P20-101 Pembrolizumab (400mg/b) q6w (head and neck cancer) PDF
P19-304 Pembrolizumab/CBDCA/5-FU triweekly PDF
P19-304 Pembrolizumab/FP triweekly PDF
P16-101 PTX weekly (head and neck cancer) PDF

Cancer chemotherapy regimen brain tumor

Update date and time: November 24, 2023

B15-102 Bev biweekly (recurrence) PDF
B15-102 Bev triweekly (monotherapy phase) PDF
C14-201 CARE PDF
E14-302 ICE PDF
T19-101 TMZ(150mg/m2) div(d1-5) q4w PDF

Cancer chemotherapy regimen brain tumor tumor

Last updated: April 4, 2024

A15-103 ADM triweekly PDF
A15-202 ADM/IFM triweekly PDF
D17-201 DTX(d8)/GEM(d1,8) triweekly PDF
E16-101 Eribulin (d1,8) triweekly (malignant soft tissue tumor) PDF
T16-101 Trabected in triweekly PDF

Cancer chemotherapy regimen skin cancer

Update date and time: November 29, 2023

D15-101 DTIC (250mg/m2) (d1-5) monthly PDF
D16-101 DTX triweekly (Paget's disease) PDF
D16-101 DTX weekly (Paget's disease) PDF
I18-101 Ipilimumab triweekly PDF
N18-203 Nivo/Ipi triweekly (malignant melanoma) PDF
N23-101 Nivolumab(480mg/b) q4w (malignant melanoma) PDF
N18-102 Nivolumab biweekly (malignant melanoma) PDF
P23-101 Pembrolizumab (400mg/b) q6w (malignant melanoma) PDF
P19-101 Pembrolizumab triweekly (malignant melanoma) PDF
P16-101 PTX weekly (Paget's disease) PDF

Cancer chemotherapy regimen cancer of unknown primary

Update date: May 19, 2022

G15-201 GEM (d1,8)/CPT-11(d1,8) triweekly PDF

Cancer chemotherapy regimen Neuroendocrine tumors

Last updated: April 4, 2024

S17-203 ADM (d1, 22)/STZ (d1-5) every 6 weeks PDF
C22-301 CVD therapy triweekly PDF
S17-203 5-FU (d1-5)/STZ (d1-5) every 6 weeks PDF
S18-103 Streptozocin weekly PDF

Cancer chemotherapy regimen MSI-High

Update date: May 19, 2022

P20-101 Pembrolizumab (400mg/b) q6w (MSI-H) PDF
P18-101 Pembrolizumab triweekly (MSI-High) PDF

To doctors at regional medical institutions

Various workshops are held with the aim of deepening cooperation between out-of-hospital pharmacies and hospitals and sharing information to ensure the safety of drug therapy. In addition, we will strengthen drug-drug collaboration by sharing information using medication information sheets (tracing reports). When you introduce a patient, please instruct them to carry a medicine notebook or use an electronic medicine notebook.

About the use of medical records

About the use of medical records

Notice regarding implementation of clinical research for patients undergoing medical examination at our hospital

Currently, the Department of Pharmacy is conducting the following clinical research.

In this research, we will use the data (information) obtained from the patient's daily clinical practice.

If you object to the use of your data for this research, you can stop using the information at any time. If you would like to know more about the research plan or content, if you have any objections to the use of your data in this research, or if you have any other questions, please contact us at the contact information below. .

Research subject Description (PDF)
Consideration of multidose vials for multiple use of single vials in robotic preparation of anticancer drugs PDF
Impact of increased frequency of AST conferences on antibiotic stewardship PDF
Efforts and effects of optimizing antibiotics for infection prevention in tympanoplasty PDF
Research on the usefulness of pharmacist-assisted test input support for early detection of adverse events caused by immune checkpoint inhibitors PDF
Efforts regarding proper use based on pharmacist intervention cases in the psychiatric liaison team PDF
Effects of long-term administration of voriconazole injection on renal function in patients with renal dysfunction PDF
Risk factor search for adverse events of PARP inhibitors in ovarian cancer patients and blood concentration analysis PDF
Investigation on the time to start pralidoxime administration in organophosphate poisoning and its effect on recovery of cholinesterase level PDF
Investigation of administration of rivaroxaban for Trousseau syndrome in diabetic patients PDF
Fact-finding survey of therapeutic agents for coronary artery disease in acute care hospitals PDF
Fact-finding survey on the combined use of lipid emulsions during total parenteral nutrition in acute care hospitals PDF
Fact-finding survey of hypertriglyceridemia caused by administration of propofol in ICU PDF
A study on the significance of dose reduction to avoid treatment discontinuation due to side effects of lenvatinib for hepatocellular carcinoma PDF
Examination of pharmacological problems in post-ICU patients PDF
Investigation on the usefulness and safety of adrenaline administration for the prevention of anaphylactic reactions with viper antitoxin PDF
Pharmaceutical management of SGLT2 inhibitors in perioperative support centers PDF
Development of skin disorders caused by apalutamide, a therapeutic drug for prostate cancer, and investigation of risk factors in clinical practice PDF
Analysis of pharmacist work in prehospital preparation center and verification of its usefulness PDF
Fact-finding survey of patients transported by ambulance for type 2 diabetic ketoacidosis PDF
Effect of Oral Diabetes Agent SGLT2 Inhibitor on Postoperative Acidosis PDF
Whole blood concentration prediction of immunosuppressant tacrolimus considering erythrocyte count fluctuation in hematopoietic stem cell transplantation PDF
Exploring factors that affect hemoglobin level fluctuations in allogeneic hematopoietic stem cell transplant patients PDF
Examination of risk factors for lymphopenia in bendamustine-treated patients PDF
Pharmacokinetic study of remdesivir in severe COVID-19 patients PDF
Pharmacokinetic study of favipiravir in severe COVID-19 patients PDF
Construction of treatment-related database of vancomycin-administered patients, extraction of influencing factors on pharmacokinetics using the database, and expansion of optimization of population parameters PDF
Population pharmacokinetic model analysis of methotrexate in hyper-CVAD/MA therapy PDF
A retrospective study on the effect of rikkunshito on malnutrition after gastrectomy PDF
Examination of MSI-High expression status and efficacy and safety of pembrolizumab administration in Japanese patients with solid tumors PDF
Adverse event evaluation of enzalutamide dose escalation in castration-resistant prostate cancer PDF
PK/PD model analysis of neutropenia following docetaxel plus ramucirumab combination therapy in patients with non-small cell lung cancer PDF
Blood concentration measurement and kinetic analysis for suspected cases of drug poisoning and evaluation of its usefulness PDF
Evaluation of the effect of combined lipid emulsion on liver function during total parenteral nutrition in an acute care hospital PDF
Efficacy and safety evaluation of dose-dense TC therapy in patients with diabetes and ovarian cancer PDF
Verification of aroma treatment effects of complementary and alternative medicine (CAM) as integrative medicine in palliative care PDF
Evaluation of Fall Risk of Suvorexant and Other Sedative Hypnotics PDF
Issues in Tracing Report Operation at Kobe City Medical Center General Hospital and Examination of Countermeasures PDF
Construction of a pharmacokinetic model for immune checkpoint inhibitors in patients with non-small cell lung cancer PDF
Study on conversion from hydromorphone injection to oral formulation PDF
Investigation on enhancement of the effect of warfarin by concomitant use of fentanyl PDF
Efforts of pharmacists as hepatitis medical coordinators at medical institutions specializing in liver diseases PDF
Antimicrobial Stewardship Team Intervention Effects Based on Process and Outcome Measures PDF
Evaluation of efficacy and safety of cancer chemotherapy in diabetic patients PDF
Construction of treatment-related database of vancomycin-treated patients, extraction of influencing factors on pharmacokinetics and optimization of population parameters PDF
Investigation of side effects in administration of daptomycin and elucidation of factors affecting the occurrence of side effects PDF

news

2023 Published in Journal
book
  1. Nobuyuki Muroi: How to determine the amount of energy and nutrients administered. JSPEN Nutritional Therapy Pocketbook. Edited Japanese Society for Clinical Nutrition and Metabolism. Nankodo, Tokyo, 21-24, 2023
  2. Ryo Tamura: Ethanol. New Edition: Standard Clinical Practice Guide for Acute Poisoning. Supervised by Japanese Society for Clinical Toxicology, edited by the Academic Committee Japanese Society for Clinical Toxicology /Revision Committee of the Standard Clinical Practice Guide for Acute Poisoning. Health Publishing, Tokyo, 132-133, 2023
paper
  1. Tamura R, Irie K, Nakagawa A, Muroi H, Eto M, Ikesue H, Muroi N, Fukushima S, Tomii K, Hashida T: Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS-441524 in patients with moderate and severe COVID-19. CPT Pharmacometrics Syst Pharmacol. 12(4): 513-521, 2023
  2. Fujiwara M, Uchida M, Endo M, Goto M, Shimizu T: Cardiac adverse events associated with multiple myeloma patients treated with proteasome inhibitors. Oncology. 101(5): 343-348, 2023
  3. Irie K, Hiramoto N, Yamaoka K, Fukushima S. Cerebrospinal fluid concentration of foscarnet in patients with HHV-6 encephalitis after hematopoietic stem cell transplantation. J Antimicrob Chemother. 78(6): 1549-1551, 2023
  4. Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T. Adverse event profile of azacitidine: analysis by route of administration using Japanese pharmacovigilance database. Oncology. 101(10): 664-674, 2023
  5. Takayama Y, Kusamori K, Katsurada Y, Obana S, Itakura S, Nishikawa M. Efficient delivery of mesenchymal stem/stromal cells to injured liver by surface PEGylation. Stem Cell Res Ther. 14(1): 216, 2023
  6. Yamaoka K, Irie K, Hiramoto N, Hirabatake M, Ikesue H, Hashida T, Shimizu T, Ishikawa T, Muroi N. Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma. Invest New Drugs. 41(5): 761-767, 2023
  7. Tanaka F, Irie K, Fukui N, Horii R, Imamura H, Hirabatake M, Ikesue H, Muroi N, Fukushima S, Sakai N, Hashida T. Pharmacokinetics of temozolomide in a patient with glioblastoma undergoing hemodialysis: a short communication. Ther Drug Monit. 45(6): 823-826, 2023
  8. Dote S, Shiwaku E, Kohno E, Fujii R, Mashimo K, Morimoto N, Yoshino M, Odaira N, Ikesue H, Hirabatake M, Takahashi K, Takahashi M, Takagi M, Nishiuma S, Ito K, Shimato A, Itakura S , Takahashi Y, Negoro Y, Shigemori M, Watanabe H, Hayasaka D, Nakao M, Tasaka M, Goto E, Kataoka N, Yokomizo A, Kobayashi A, Nakata Y, Miyake M, Hayashi Y, Yamamoto Y, Hirata T, Azuma K, Makihara K, Fukui R, Tokutome A, Yagisawa K, Honda S, Meguro Y, Suzuki S, Yamaguchi D, Miyata H, Kobayashi Y. Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study. Int J Clin Oncol. 28(8): 1054-1062, 2023
  9. Katsura H, Suga Y, Kubo A, Sugimura H, Kumatani K, Haruki K, Yonezawa M, Narita A, Ishijima R, Ikesue H, Toi H, Takata N. Risk evaluation of proton pump inhibitors for panitumumab-related hypomagnesemia in patients with metastatic colorectal cancer. Biol Pharm Bull. 47(1): 98-103, 2024
  10. Takase, Y.; Yamada, K.; Kurihara, K.; Tabuchi, H.; Oyama, M.; Hashida, T.; Muroi, N.: Usefulness of simplified protocols for in-hospital responses to inquiries about prescriptions due to drug supply shortages. Medical Pharmacy 49(7): 247-253, 2023
  11. Sakuma M, Masumoto N, Yoshioka C, Ariyoshi S, Yoshino Y, Oku S, Hashida T, Hirahata M, Ikesue H, Muroi N. Analysis of pharmacist task time in a prehospitalization preparation center and verification of its usefulness. Journal of the Japanese Society of Hospital Pharmacists 59(6): 623-629, 2023
  12. Yoshihira, Y; Tamaki, R; Yamada, R; Uetake, C; Takahara, M; Omote, H; Kumagai, S; Okitsu, M; Muroi, N; Hashida, T: Evaluation of the implementation of an educational program using an evaluation sheet based on an OJT program. Jpn Pharmacol Ther. 51(5): 628-631, 2023
review
  1. Yukari Satsuma: Looking back at the national exam. Part 4: What are the key points for home-based drug use instruction? Monthly Pharmaceutical Affairs 65(13): 2701-2706, 2023
  2. Hiroaki Ikesue: Side effects of hormone therapy drugs and supportive care. Side effects of prostate cancer drugs 5. Hot flash. Monthly Pharmaceutical Affairs July 2023 Special Issue 65(10): 2057-2062, 2023
  3. Hiroaki Ikesue: Side effects of hormone therapy drugs and supportive care. Side effects of prostate cancer drugs 6. Decreased libido and erectile dysfunction. Monthly Pharmaceutical Affairs July 2023 Special Issue 65(10): 2063-2066, 2023
  4. Hiroaki Ikesue: Side effects of hormone therapy drugs and supportive care. Side effects of prostate cancer drugs 7. Gynecomastia. Monthly Pharmaceutical Affairs July 2023 Special Issue 65(10): 2067-2070, 2023
  5. Hiroaki Ikesue: Side effects of hormone therapy drugs and supportive care. Side effects of prostate cancer drugs 8. Liver dysfunction. Monthly Pharmaceutical Affairs July 2023 Special Issue 65(10): 2071-2074, 2023
  6. Hiroto Tanaka: Re-examining admission and discharge support! Pharmaceutical management with an eye to post-discharge. Activities of pharmacists at the inpatient support center. Monthly Pharmaceutical Affairs October 2023 Special Issue 65(13): 22-25, 2023
  7. Toru Hashida: Why are there so many cases of medicines being unavailable? What should pharmacists do?, Be Ambitious! Series No. 12, TURNUP 62,15, Apr.2023
  8. Toru Hashida: I'm not good at speaking in front of people. How can I give a good presentation?, Be Ambitious! Series No. 13, TURNUP 63,15, June.2023
  9. Toru Hashida: Generative AI is a hot topic! How will pharmaceutical education and the work of pharmacists change?, Be Ambitious! Series No. 14, TURNUP 64,15, Aug.2023
  10. Toru Hashida: Should Japanese pharmacists get a BS or a Pharm.D. degree?, Be Ambitious! Series No. 15, TURNUP 65,15, Oct.2023
  11. Toru Hashida: English as an international language. How can future pharmacists overcome the conversation barrier?, Be Ambitious! Series No. 15, TURNUP 66,15, Dec.2023
  12. Toru Hashida: A bright future for pharmacists, overcoming invisible barriers, Be Ambitious! Final episode, TURNUP 67,15, Feb.2024
  13. Ryo Tamura: Actual situation of antidotes and antagonists as in-hospital preparations; from the perspective of the preparation side. Toxicology Research, 36(4): 341-346, 2023
  14. Masao Munemura: Government initiatives regarding unapproved and off-label drugs and the current state of addiction treatment. Addiction Research, 36(4): 347-354, 2023
  15. Yukari Satsuma: Looking back at the national exam. What should pharmacists assess when providing medication instructions to elderly people? Monthly Pharmaceutical Affairs 66(1): 110-116, 2024

2022 Journal Announcement
book
  1. Tomotaka Takase, Nobuyuki Muroi: Introduction of the autonomous transport robot HOSPi®︎ - Active use leads to the development and improvement of medical care. Medical Affairs Sanro Research Institute. Sanro Research Institute, Tokyo, 29: 14-16, 2022
  2. Takase, Tomoki: Nutritional therapy for hospitalized patients. Monthly Pharmaceutical Affairs Special Issue, Toshiyuki Irie (ed.), Jiho, Tokyo, 64: 62-72, 2022
  3. Norio Masumoto: Type 2 diabetes. Drug therapy questions for pharmacists. Ichiro Ieiri (ed.), Jiho, Tokyo, 100-105, 2022
  4. Kei Irie: Antiandrogen drugs. Clinical Oncology Pharmacology, Japanese Society of Clinical Oncology Pharmacology (ed.), 2nd edition, Jiho, Tokyo, 251-254, 2022
  5. Hiroaki Ikesue: Immune-related adverse events (irAE). Clinical Oncology Pharmacology, Japanese Society of Clinical Oncology Pharmacology (ed.), 2nd edition, Jiho, Tokyo, 769-776, 2022
  6. Hiroaki Ikesue, Toru Hashida: Anticancer drugs. Drug list edition. Therapeutic drug handbook 2023, Shoji Hori, Kentaro Kanno, Takashi Kadowaki, Kenichi Inui, Masahiro Hayashi (eds.), Jiho, Tokyo, 1046-1173, 2023
  7. Hiroaki Ikesue: Preparation of medicines based on prescriptions (4) Chemical hazards. Hospital and pharmacy practical training textbook for pharmacy students 2023 edition, Pharmaceutical Education Council Hospital and Pharmacy Practical Training Kinki District Coordination Organization (supervisor), Japan Society of Hospital Pharmacists Kinki Block/Japan Pharmaceutical Association Osaka-Kinki Block (editor), Jiho, Tokyo, 98-199, 2023
  8. Hiroaki Ikesue: Lung cancer. Cancer chemotherapy regimen management manual, Toshihiro Hama (ed.), Tsuyoshi Aoyama, Hiroaki Ikesue, Mayako Uchida, Junya Sato, Shinya Takada, Masami Tsuchiya (eds.), 4th edition, Igaku Shoin, Tokyo, 183, 2023
  9. Hiroaki Ikesue: Head and neck cancer. Cancer chemotherapy regimen management manual, Toshihiro Hama (ed.), Tsuyoshi Aoyama, Hiroaki Ikesue, Mayako Uchida, Junya Sato, Shinya Takada, Masami Tsuchiya (eds.), 4th edition, Igaku Shoin, Tokyo, 733, 2023
  10. Shintaro Yoshino: Lung cancer (29) Gefitinib (30) Erlotinib (31) Afatinib (32) Osimertinib. Cancer chemotherapy regimen management manual, Toshihiro Hama (editor), Tsuyoshi Aoyama, Hiroaki Ikesue, Mayako Uchida, Junya Sato, Shinya Takada, Masami Tsuchiya (editors), 4th edition, Igaku-Shoin, Tokyo, 222-236, 2023
paper
  1. Hirabatake M, Mizuno T, Kato K, Hashida T: Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer. Front Pharmacol. 13: 984002, 2022
  2. Hirabatake M, Ikesue H, Iwama Y, Irie K, Yoshino S, Yamasaki T, Hashida T, Kawakita M, Muroi N: Pharmacist–urologist collaborative management improves clinical outcomes in patients with castration-resistant prostate cancer receiving enzalutamide. Front Pharmacol. 13 : 901099, 2022
  3. Takase T, Tsugawa N, Sugiyama T, Ikesue H, Eto M, Hashida T, Tomii K, Muroi N: Association between 25-hydroxyvitamin D levels and COVID-19 severity in Japanese patients. Clinical Nutrition ESPEN. 49: 256-263, 2022
  4. Takase T, Masumoto N, Shibatani N, Matsuoka Y, Tanaka F, Hirabatake M, Kashiwagi H, Nishioka I, Ikesue H, Hashida T, Koide N, Muroi N: Evaluating the safety and efficiency of robotic dispensing systems. J Pharm Health Care Sci. 8: 24, 2022
  5. Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T: Comprehensive analysis of ixazomib-induced adverse events using the Japanese pharmacovigilance database. Oncology. 100: 413-418, 2022
  6. Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T: Comprehensive analysis of adverse events induced by PARP inhibitors using JADER and time to onset. Life. 12: 1355, 2022
  7. Hiya S, Fujiwara S, Tanaka F, Kohara N, Kawamoto M: High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis. eNeurological Sci. 27: 100404, 2022
  8. Hasegawa S, Ikesue H, Satake R, Inoue M, Yoshida Y, Tanaka M, Matsumoto K, Wakabayashi W, Oura K, Muroi N, Hashida T, Iguchi K, Nakamura M: Osteonecrosis of the jaw caused by denosumab in treatment-naïve and pre-treatment with zoledronic acid groups: a time-to-onset study using the Japanese Adverse Drug Event Report (JADER) database. Drugs – Real World Outcomes. 9: 659-665, 2022
  9. Irie K, Hiramoto N, Ishikawa T, Fukushima S: Use of liquid chromatography-tandem mass spectrometry for foscarnet quantification in human serum and cerebrospinal fluid. Rapid Commun Mass Spectrom. 36: e9255, 2022
  10. Nishioka H, Cho Y, Irie K, Kanamori M: Ceftriaxone-associated encephalopathy in a patient with high levels of ceftriaxone in blood and cerebrospinal fluid. Int J Infect Dis. 116: 223-225, 2022
  11. Maeda A, Ando H, Irie K, Hashimoto N, Morishige JI, Fukushima S, Okada A, Ebi H, Matsuzaki M, Iwata H, Sawaki M: Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. Eur J Clin Pharmacol. 78: 1239-1247, 2022
  12. Minamii T, Shimizu H, Irie K, Nishioka H: Encephalopathy induced by high levels of ceftriaxone in the blood and cerebrospinal fluid. IDCases. 29: e01581, 2022
  13. Tohi M, Irie K, Mizuno T, Okuyoshi H, Hirabatake M, Ikesue H, Muroi N, Eto M, Fukushima S, Tomii K, Hashida T: Population pharmacokinetics of nivolumab in Japanese real-world patients with non-small cell lung cancer Ther Drug Monitor. 45: 110-116, 2023
  14. Maeda A, Ando H, Irie K, Hashimoto N, Morishige JI, Fukushima S, Okada A, Ebi H, Matsuzaki M, Iwata H, Sawaki M: Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib metabolites (M2, M20, M18). Anticancer Res. 43: 1283-1289, 2023
  15. Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Shimizu T: The influence of the rapid increase in the number of adverse event reports for COVID-19 vaccine on the disproportionality analysis using JADER. In Vivo. 37: 345-356, 2023
  16. Tsujimoto Tsutomu, Hatae Takashi, Okusada Satoshi, Tomita Rika, Mutsumura Ryusuke, Kuroda Yasuji, Tsuneyoshi Keiko, Satake Masako, Masumoto Norio: Survey on understanding and instruction of insulin subcutaneous induration among hospital pharmacists and pharmacy pharmacists. Medicine and Diabetes 11: 61-71, 2022
review
  1. Takase, Y., Tsugawa, N., Sugiyama, M., Ikesue, H., Eto, M., Hashida, T., Tomii, K., and Muroi, N.: Association between blood 25-hydroxyvitamin D levels and COVID-19 severity. Vitamin 96: 471-473, 2022
  2. Ryo Tamura, Naohiro Yoshihiro: Drug administration during blood purification therapy. Emergency and Intensive Care 34: 1560-1567, 2022
  3. Ryo Tamura: How to use drugs in cardiac arrest using the ABCD approach. Monthly Pharmaceutical Affairs 64: 55-62, 2022
  4. Ryo Tamura: Intensive care: Effect of dexamethasone 12 mg vs. 6 mg on survival time without life support in adult COVID-19 patients with severe hypoxemia. Monthly Pharmaceutical Affairs 64: 199-200, 2022
  5. Toru Hashida and Yasuki Kihara: How to cover the costs of cutting-edge medical care based on the experience of national strategic special zones. Hospital 81: 584-587, 2022
  6. Mai Ikemura, Toru Hashida: Recommendations for research activities to become a pharmacist active in the medical field. Pharmaceutical Education 6: 2022-022, 2022
  7. Hiroaki Ikesue, Nobuyuki Muroi: Ensuring the safety of cancer chemotherapy through collaboration with pharmacists. Clinical and Research 99: 1011-1015, 2022
  8. Kei Irie: Pharmacokinetic study of antiviral drugs in COVID-19 patients. YAKUGAKU ZASSHI 143: 239-241, 2023

Fiscal year 2021 Announced in the magazine
book
  1. Toru Hashida (supervisor), Nobuyuki Muroi (eds.) Monthly special issue of pharmaceutical affairs. Strengthening book for first-year pharmacists. 2021.
  2. Nobuyuki Muroi. Types, composition, and characteristics of parenteral nutrition.JSPEN Textbook Japanese Society for Clinical Nutrition and Metabolism, 2021.
  3. Hiroaki Ikesue, Toru Hashida. Laxatives (laxatives). “New and different!
  4. Hiroaki Ikesue, Toru Hashida. The role of pharmacists. Handbook for the treatment of rare and intractable cancers.
  5. Nobuyuki Muroi, Toru Hashida. Development of pharmacists through the resident system. Pharma-Lead Next. 2: 2-5, 2022
  6. Okusada Satoshi. Kihon pharmacotherapy (1) (oral drugs, incretin-related drugs). Diabetes Care+. 19: 79-84, 2022
  7. Ikesue, Hiroaki. Preparation of pharmaceuticals based on prescriptions. (4) Chemical hazards.
paper
  1. Miura R, Hirabatake M, Irie K, Ikesue H, Muroi N, Kawakita M, Hashida T. Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer. Urol Oncol. 39: 233.e15-233.e20 , 2021
  2. Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, Yamamoto S, Takenobu T, Tomii K, Kawakita M, Katoh H, Ishikawa T, Yasui H, Hashida T. Associated characteristics and treatment outcomes of medication- related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Support Care Cancer. 29: 4763-4772, 2021
  3. Tanaka F, Shibatani N, Fujita K, Ikesue H, Yoshimizu S, Muroi N, Kurimoto Y and Hashida T. Polypharmacy-associated potential contraindications of drug prescriptions in patients with primary angle closure disease in a real-world setting. J Pharm Health Care Sci.7: 17, 2021
  4. Yamashita K, Shimomura Y, Ikesue H, Muroi N, Yoshimoto A, Hashida T. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study. BMC Infect Dis. 21: 664, 2021
  5. Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, Muroi N, Fukushimab S, Tomii K, Hashida T. Population pharmacokinetics of favipiravir in patients with COVID-19. CPT Pharmacometrics Syst Pharmacol. 10: 1161- 1170, 2021
  6. Inoue M, Matsumoto K, Tanaka M, Yoshida Y, Satake R, Goto F, Shimada K, Mukai R, Hasegawa S, Suzuki T, Ikesue H, Liao J, Hashida T, Nakamura M. Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database. Sci Rep. 11: 11324, 2021
  7. Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemother Pharmacol.87: 871-877, 2021
  8. Satake R, Matsumoto K, Tanaka M, Mukai R, Shimada K, Yoshida Y, Inoue M, Hasegawa S, Iguchi K, Ikesue H, Shimizu S, Nishida S, Suzuki A, Hashida T, Nakamura M. Analysis of drug-induced gastrointestinal obstruction and perforation using the Japanese Adverse Drug Event Report Database. Front Pharmacol. 12: 692292, 2021
  9. Ogata M, Ama Y, Ogata T, Hirabatake M, Yasui H, Satake H. Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active cancer. In Vivo. 35: 2747-2753, 2021
  10. Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched Analysis. Support Care Cancer. 30: 2341-2348, 2021
  11. Ikesue H, Yamamoto H, Hirabatake M, Hashida T, Chung H, Inokuma T, Muroi N. Risk factors of proteinuria in patients with hepatocellular carcinoma receiving lenvatinib. Biol Pharm Bull. 45: 333-338, 2022
  12. Ikesue H, Yamaoka K, Matsumoto A, Hirabatake M, Muroi N, Yamasaki T, Kawakita M, and Hashida T. Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. Cancer Chemother Pharmacol. Online ahead of print
  13. Eriko Kuramoto, Nobuyuki Muroi, Masaki Hirabatake, Haruna Hirayama, Naoki Shibatani, Asako Kii, Yasuo Kurimoto, Toru Hashida. Applicability of cefcapene pivoxil tablets as a postoperative prophylactic antibacterial agent in the clinical path of Ophthalmology day Japanese Society of Chemotherapy Journal. 69: 249-254, 2021
  14. Tomoya Tanaka, Yasuko Kurata, Naotake Takase, Mayuko Himoto, Toru Shinmen, Kazuki Dan, Makoto Kajizono, Yasuyuki Masaoka, Akihiko Nakamoto, Hideki Nawa, Yoshihisa Kitamura, Hiroaki Ikesue, Nobuyuki Muroi, Toshiaki Sendo, Miki Ikuko. A study of risk factors for proteinuria in patients treated with ramucirumab.
  15. Kunitaka Matsuishi, Haruko Fukushima, Kyohei Otani, Hiroyuki Miyai, Shigeru Tsuruya, Shuji Kawamura, Toshimichi Takahashi, Yoshiko Kuwata. Impact and countermeasures against the corona disaster in the clinical setting of the neuropsychiatric department of a general hospital with a new coronavirus infectious disease ward. Psychiatry Journal. 32: 829-836, 2021
  16. Hirohito Hama, Masaki Hirabatake, Hiroaki Ikesue, Nobuyuki Muroi, Toru Hashida. Consideration of expiration date setting for introduction of drug vial optimization. Cancer and Chemotherapy. 48: 1139-1143, 2021
  17. Kinoshita M., Ophthalmology N., Miyasaka M., Oe T., Hirano T., Irie K., Yoshimizu S., Fujiwara M., Kurimoto Y., Muroi N. Evaluation of ``glaucoma pharmacist outpatient services'' for glaucoma patients. 1113, 2021
review
  1. Muroi Nobuyuki. What is hospital practical training that leads to the development of clinical pharmacists? Pharmaceutical Education. 5: 2020-2024, 2021
  2. Nobuyuki Muroi. Community collaboration for patients with low vision: Low vision care linking hospitals to communities and the role of pharmacists. Pharmacy. 72: 2489-2493, 2021
  3. Ohe Y. Drug management seen by low vision patients. Pharmacy. 72: 2453-2457, 2021
  4. Tanaka I. Proposal of medicines requiring attention and alternative medicines for glaucoma. Pharmacy. 72: 2458-2464, 2021.
  5. Miyasaka M. Basic knowledge of eye drops. Pharmacy. 72: 2466-2472, 2021
  6. Naoki Shibatani. Development of ophthalmic device to support patients with low vision. Pharmacy. 72: 2473-2478, 2021
  7. Hirano T. Establishment and efforts of glaucoma pharmacist outpatient clinic. Pharmacy. 72: 2495-2505, 2021
  8. Yamada Kiyofumi, Hashida Toru. Direction of postgraduate pharmacist training. Journal of the Japanese Society of Hospital Pharmacists. 57: 1190-1196, 2021
  9. Ikesue H. Adverse drug monitoring and supportive care of anticancer drugs. Dispensing and information. 27: 1999-2004, 2021
  10. Ikesue H. Various situations in which cancer drug therapy becomes difficult to continue. Pharmacy. 72: 3326-3329, 2021
  11. Fujita T. Hand disinfection, article disinfection. Dispensing and information. 27: 2678-2683, 2021
  12. Tamura R. Home visit response to home care patients. Dispensing and information. 27: 2714-2718, 2021
  13. Muroi N, Yasuda Rie. Responding to mass vaccination of COVID-19 vaccines in communities. Dispensing and information. 27: 2719-2723, 2021

2020 Magazine announcement
book
  1. Ikesue H, Ito Y, Oishi R. Cancer chemotherapy worksheet 5th edition. Jiho, Tokyo, 2020
  2. Yukari Satsuma, Tatsuya Hirano: CQ6, CQ16: 2020 Guideline for Pharmacological Treatment of Cancer Pain, The Japanese Society for Palliative Medicine Guideline Management Committee (Editor), Kanehara Publishing, Tokyo, 2020
  3. Masatoshi Jinno, Hiroaki Ikesue (supervisor), Hiroyuki Watanabe (author). Evidence-based guidance for the development and management of cancer chemotherapy regimens. Yodosha, Tokyo, 2020
  4. Hiroaki Ikesue. Pharmaceutical Education Council Hospital and Pharmacy Practical Training Kinki District Coordination Organization (supervision). Hospital and pharmacy practical training textbook for pharmacy students 2021 edition. Prescription-based drug preparation. (4) Chemical Hazard. 94-96 , Jiho, Tokyo, 2021
  5. Hiroaki Ikesue. "Illnesses and medicines 2021" Anticancer drugs. 1480-1495, Nanzando, Tokyo, 2021
paper
  1. Takase T, Ikesue H, Nakagawa H, Kinoshita M, Muroi N, Kitai T, Furukawa Y, Hashida T. Effect of the number of dose adjustment factors on bleeding risk in patients receiving 30 mg/day edoxaban. J Clin Pharm Ther. 45 : 298–302, 2020
  2. Ikesue H, Kusuda K, Satsuma Y, Nishiwaki F, Miura R, Masuda Y, Hirabatake M, Muroi N, Fujimoto D, Morimoto T, Tomii K, Hashida T. Evaluation of the usefulness of protocol-based pharmacist-facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer. J Clin Pharm Ther. 45: 6, 1288-1294, 2020
  3. Torii H, Ando M, Tomita H, Kobaru T, Tanaka M, Fujimoto K, Shimizu R, Ikesue H, Okusada S, Hashida T, Kume N. Association of hypnotic drug use with fall incidents in hospitalized elderly patients: a case-crossover study. Biol Pharm Bull. 43: 925-931, 2020
  4. Ando M, Nishioka H, Nakasako S, Kuramoto E, Ikemura M, Kamei H, Sono Y, Sugioka N, Fukushima S, Hashida T. Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation. J Clin Pharm Ther. 45: 290-297, 2020
  5. Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, Muroi N, Tomii K, Hashida T. Pharmacokinetics of favipiravir in critically ill patients with COVID-19. Clin Transl Sci. 13: 880-885, 2020
  6. Uchida M, Yamaguchi Y, Hosomi S, Ikesue H, Mori Y, Maegawa N, Takano A, Sato Y, Hosohata K, Muroi N, Tomii K, Hashida T, Nakamura T. Risk factors for febrile neutropenia induced by docetaxel chemotherapy in patients with non-small cell lung cancer. Biol Pharm Bull. 43: 1235-1240, 2020
  7. Uchida M, Mori Y, Akiba K, Miyasaka M, Hirano T, Ikesue H, Yamaguchi Y, Takano A, Maegawa N, Shimomura Y, Hosohata K, Muroi N, Ishikawa T, Hashida T, Nakamura T. Risk factors for skin toxicities associated with bendamustine-based chemotherapy in patients with non-Hodgkin lymphoma. Biol Pharm Bull. 43: 10, 1577-1582, 2020
  8. Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Inoue M, Satake R, Yoshida Y, Goto F, Hashida T, Nakamura M. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiol Drug Saf. 29: 1279–1294, 2020
  9. Satsuma Y, Ikesue H, Kusuda K, Maeda M, Muroi N, Mori R, Kogo M, Hirabayashi R, Nagata K, Nakagawa A, Tachikawa R, Tomii K, Hashida T. Effectiveness of pharmacist-physician collaborative management for patients with idiopathic pulmonary fibrosis receiving pirfenidone. Front Pharmacol, 11:529654, 2020
  10. Matsumoto K, Hasegawa S, Nakao S, Shimada K, Mukai R, Tanaka M, Satake R, Yoshida Y, Goto F, Inoue M, Ikesue H, Iguchi K, Hashida T, Nakamura, M. Adverse event profile of Reye's syndrome analyzed using the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases. SAGE Open Medicine, 8: 1–9, 2020
  11. Yoshida S, Fujimoto A, Fukushima K, Ando M, Irie K, Hirano T, MiyasakaM, Shimomura Y, Ishikawa T, Ikesue H, Muroi N, Hashida T, Sugioka N. Population pharmacokinetics of tacrolimus in umbilical cord blood transplant patients focusing on patients the variation in red blood cell counts. J Clin Pharm Ther. 46: 190-197, 2021
  12. Ohne M, Satsuma Y, Umeda S, Shinjo T, Nishimoto T, Ikesue H, Muroi N, Hashida T. Study on conversion from hydromorphone injection to oral formulation. Journal of The Japanese Society for Palliative Medicine. 15: 147- 151, 2020
  13. Nobori K, Doi M, Fujii N, Kii A, Muroi N, Hashida T. A case of HIV-infected very low birth weight infants treated with antiretroviral therapy (ART). Journal of the The Japanese Society for AIDS Research. 22: 106-110, 2020
  14. Makiko Doi, Hiroaki Nishioka, Madoka Ibaraki, Hiroaki Ikesue, Motozumi Ando, Naoki Higashibeppu, Nobuyuki Muroi, Toru Hashida. Appropriate total parenteral nutrition prescription by the nutritional support team -A study at our hospital-. JSPEN. 2 : 227-223, 2020
review
  1. Toru Hashida, Takashi Osawa, Koji Kashiwakura. Challenges and future prospects for medical economics with drugs. Pharmaceutical Sciences. 80: 229-232, 2020
  2. Muroi, Nobuyuki. Seamless collaboration in the transitional period such as hospital admission/discharge/perioperative period: drug therapy and pharmacist's role from hospital to community. Dispensing and information. 26: 1204-1211, 2020
  3. Muroi Nobuyuki. Pathophysiology and therapeutic agents for allergic rhinitis.
  4. Kazuko Tobiko, Nobuyuki Muroi. Column How should we consider the polypharmacy of cardiovascular drugs in an aging society. medicina. 58: 140-141, 2020
  5. Hiroaki Ikesue. Side effects of anticancer drug therapy series No. 4. Side effect management: immune-related adverse events (irAE). Japanese Journal of Clinical Oncology. 17: 11-19, 2020
  6. Ikesue Hiroaki. Efforts of education for understanding and disseminating evidence in clinical practice. Pharmaceutical Education. 4: 2020-035, 2020
  7. Muguruma R., Oku S., Tomita R., Masumoto N., Kuroda T., Tsujimoto T. Activity report in Hyogo Prefecture (Hyogo Prefecture Federation of Diabetes Educators). Medicine and Diabetes. 9: 201-206, 2020

2019 Magazine announcement
book
  1. Haruna Yamamoto: Anti-HCV drug. Drug interaction literacy for medical practice, Yoshiyuki Ohno, Akihiro Hisaka (editors), Nanzando, Tokyo, 184-188, 2019
  2. Daisuke Mioki: Guidance records for high-risk drugs. How to write a simple and easy-to-understand drug history and guidance record, Tadashi Terasawa (ed.), Nanzando, Tokyo, 90-101, 2019
  3. Hiroaki Ikesue: VEGF pathway inhibitor (angiogenesis inhibitor: polymer drug). Organizing and understanding anticancer drugs, Toshihiro Hama (supervisor), Jiho, Tokyo, 138-148, 2019
  4. Yoko Makihara, Hiroaki Ikesue: Lesson 8 Dealing with constipation. Learning from basic knowledge and cases: how to use drugs in palliative care for cancer, Yoshiaki Okamoto, Sachiko Arai (editors), Jiho, Tokyo, 112-119, 2019
  5. Ikesue H, Hashida T: Anti-cancer drugs. Therapeutic Drug Handbook 2020, Fumimaro Takahisa (supervisor), Jiho, Tokyo, 1008-1108, 2020
  6. Hiroaki Ikesue: Preparation of pharmaceuticals based on prescriptions. (4) Chemical hazards. Hospital and pharmacy practical training textbook for pharmacy students 2020 edition, Pharmaceutical Education Council.
paper
  1. Ando M, Nakasako S, Ariyoshi K, Yamaguchi M, Sakizono K, Minowa K, Fukushima S, Sugioka N, Hashida T: Re-elevation of serum amlodipine level after lipid emulsion therapy in an overdose case. J Clin Pharm Ther. 44: 970-973, 2019
  2. Takase T, Ikesue H, Nakagawa H, Kinoshita M, Muroi N, Kitai T, Furukawa Y, and Hashida T: Risk factors for major bleeding and clinically relevant non-major bleeding in Japanese patients treated with edoxaban. Biol Pharm Bull. 458-462, 2020
  3. Nakao S, Hasegawa S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Uranishi H, Masuta M, Ikesue H, Hashida T, Iguchi K, Nakamura M: Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. Int J Med Sci. 17: 921-930, 2020
  4. Ando M, Hirabatake M, Yasui H, Fukushima S, Sugioka N, Hashida T. A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry. Biomed Chromatogr. 34: 3, e4776, 2020.
  5. Norio Masumoto, Yumiko Hisai, Kengo Hosomi, Yuki Sugita, Sachiko Komaki, Tomoko Inada, Hiroo Ohtsuki, Yusuke Nakagawa: A study on the usefulness of self-injection of liraglutide on admission in short-term hospitalized diabetic patients for coronary artery stent placement. Medications and Diabetes. 8: 299-306, 2019
review
  1. Nobuyuki Muroi: Evaluation of Diabetes Treatment and Management of Complications and Side Effects 　Evaluation of diet and exercise therapy in diabetes and its response. Pharmacy. 70: 1583-1587, 2019
  2. Nobuyuki Muroi: Basic knowledge of devices used in infusion and nutrition therapy. Pharmacy. 70: 1728-1732, 2019
  3. Haruna Yamamoto: A hospital pharmacist plays an active role as a hepatitis co. Hepatitis Medical Co Koredake - from the basics to examples of activities that make use of strengths that all occupations can be seen at a glance. Health, Labor and Welfare Research Grant "Study on verification and expansion of effectiveness of hepatitis measures from taking hepatitis virus test to receiving medical treatment" (Representative researcher: Yuichiro Eguchi) 2019 report
  4. Hiroaki Ikesue: Preoperative withdrawal of angiogenesis inhibitors. Monthly Yakuji special issue. 61: 2627-2628, 2019
  5. Hiroaki Ikesue: Measures against stomatitis caused by cancer treatment. Monthly Yakuji special issue. 61: 2629-2630, 2019
  6. Ikesue, H.: Methods of administration of G-CSF preparations. Monthly Yakuji special issue. 61: 2631-2632, 2019
  7. Kazuko Nobori: ACE inhibitor, ARB. HEART nursing. 32: 6-12, 2019
  8. Naoki Shibatani, Nobuyuki Muroi: Introduction to Kobe Eye Center Hospital Pharmacy Department and Efforts to Provide Medication Guidance to Low Vision Patients. Journal of the National Council of Municipal Hospitals. 58: 611-614, 2019

2018 Magazine announcement
book
  1. Muroi, Nobuyuki, Himoto, Mayuko, Takase, Naotake: Establishment of New Employee Education System by Introducing Tutor System - Making Use of Reflections from the Previous Year -. Theory and Practice of Hierarchical Human Resource Development in the Pharmaceutical Department, Tomohide Akase (ed.), Yakuzemi Farm Book, Saitama, 66-67, 2018
  2. Nobuyuki Muroi: Influence factors of adverse drug reactions. Environmental factors: nutritional status, diet, luxury goods, and polypharmacy. Assessment of Adverse Drug Reactions, Japanese Society of Drug Safety (supervisor), Nanzando, Tokyo, 40-43, 2019
  3. Nobuyuki Muroi: Influence factors of adverse drug reactions. Disability assessment. Scene 2 Shock caused by oxaliplatin (platinum drug) was suspected! . Assessment of Adverse Drug Reactions, Japanese Society of Drug Safety (supervisor), Nanzando, Tokyo, 86-89, 2019
  4. Nobuyuki Muroi: Influence factors of adverse drug reactions. General disability assessment. Scene 4 Suspected shock caused by infliximab (antibody drug)! . Assessment of Adverse Drug Reactions, Japanese Society of Drug Safety (supervisor), Nanzando, Tokyo, 95-98, 2019
  5. Nobuyuki Muroi: Influence factors of adverse drug reactions. Blood and hematopoietic disorder assessment. Scene 2 Granulocytopenia due to fluorouracil (anticancer drug) was suspected! . Assessment of Adverse Drug Reactions, Japanese Society of Drug Safety (supervisor), Nanzando, Tokyo, 153-156, 2019
  6. Hiroaki Ikesue: Preparation of pharmaceuticals based on prescriptions. (3) Chemical hazards. Hospital and Pharmacy Practical Training Textbook for Pharmaceutical Students 2019 Edition, Pharmaceutical Education Council, Hospital and Pharmacy Practical Training Kinki District Coordination Organization (supervisor), Jiho, Tokyo, 82-85, 2019
  7. Hiroaki Ikesue, Toru Hashida: Anticancer drugs. Therapeutic Drug Handbook 2019, Fumimaro Takahisa (supervisor), Jiho, Tokyo, 1008-1108, 2019
  8. Hirahata, M.: Venous thromboembolism. Clinical Oncology, Japanese Society of Clinical Oncology (ed.), Jiho, Tokyo, 657-663, 2019
  9. Ikesue, H.: Immune-related adverse events (irAEs). Clinical Oncology, Japanese Society of Clinical Oncology (ed.), Jiho, Tokyo, 769-776, 2019
paper
  1. Takase T, Ikesue H, Tohi M, Ueta H, Mima H, Koyama T, Hashida T: Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery. J Pharm Health Care Sci. 4: 13, 2018
  2. Yamamoto H, Ikesue H, Ikemura M, Miura R, Fujita K, Chung H, Suginoshita Y, Inokuma T, Hashida T: Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. J Pharm Health Care Sci. 4: 17, 2018
  3. Ikesue H, Nagano T, Hashida T: A case of acute kidney injury associated with dabrafenib and trametinib treatment for metastatic melanoma. Ann Pharmacother. 52: 1051-1052, 2018
  4. Irie K, Shobu S, Hiratsuji S, Yamasaki Y, Nanjo S, Kokan C, Hata A, Kaji R, Masago K, Fujita S, Okada Y, Katakami N, Fukushima S: Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: Application to finger-prick clinical blood samples of patients with non-small cell lung cancer. J Chromatogr B Analyt Technol Biomed Life Sci. 1087-1088: 1-5, 2018
  5. Irie K, Okada A, Yamasaki Y, Kokan C, Hata A, Kaji R, Fukushima K, Sugioka N, Okada Y, Katakami N, Fukushima S: An LC-MS/MS method for absolute quantification of nivolumab in human plasma: application to clinical therapeutic drug monitoring. Ther Drug Monit. 40: 716-724, 2018.
  6. Okada A, Kariya M, Irie K, Okada Y, Hiramoto N, Hashimoto H, Kajioka R, Maruyama C, Kasai H, Hamori M, Nishimura A, Shibata N, Fukushima K, Sugioka N: Population pharmacokinetics of vancomycin in patients undergoing allogeneic Hematopoietic stem-cell transplantation. J Clin Pharmacol. 58: 1140-1149, 2018
  7. Masago K, Irie K, Fujita S, Imamichi F, Okada Y, Katakami N, Fukushima S, Yatabe Y: Relationship between paronychia and drug concentrations of epidermal growth factor receptor tyrosine kinase inhibitors. Oncology. 95: 251-256, 2018
  8. Oshima E, Mibu M, Kubota M, Hashida T: Use of supplements by Japanese cancer patients receiving outpatient cancer chemotherapy. J Altern Complement Med. 24: 1003-1006, 2018
  9. Torii H, Shimizu R, Tanizaki Y, Omiya Y, Yamamoto M, Kamiike S, Yasuda D, Hiraoka Y, Hashida T, Kume N: Effects of ramelteon and other sleep-promoting drugs on serum low-density lipoprotein and non-high- density lipoprotein cholesterol: A retrospective comparative pilot study. Biol Pharm Bull. 41: 1778-1790, 2018
  10. Fujimoto K, Iwakura T, Aburaya M, Matsuoka N: Twice‑daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study. Diabetology & Metabolic Syndrome. 10: 64, 2018
  11. Kotake T, Satake H, Okita Y, Hatachi Y, Hamada M, Omiya M, Yasui H, Hashida T, Kaihara S, Inokuma T, Tsuji A: Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection. Asia Pac J Clin Oncol. 15: 63-68, 2018
  12. Hirabayashi R, Fujimoto D, Satsuma Y, Hirabatake M, Tomii K: Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report. Invest New Drugs 36: 952-954, 2018
  13. Maeda A, Irie K, Ando H, Hasegawa A, Taniguchi H, Kadowaki S, Muro K, Tajika M, Aoki M, Inaguma K, Kajita M, Fujimura A, Fukushima S: Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms. Cancer Chemother Pharmacol. 83: 107-113, 2019
  14. Irie K, Okada A, Masuda Y, Fukushima K, Sugioka N, Okuda C, Hata A, Kaji R, Okada Y, Katakami N, Fukushima S: Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy. J Oncol Pharm Pract. 25: 865-868, 2019
  15. Eriko Kuramoto, Masaki Hirabatake, Shinji Nakayoku, Motozumi Ando, Hiroaki Ikesue, Yuzo Hirai, Asako Yoshii, Toru Hashida: Efforts toward proper use of oral antibiotics after day surgery in the field of dentistry and their effects. Medical Pharmacy. 44: 422-428, 2018
  16. Yuki Takase, Hiroaki Ikesue, Misaki Kataoka, Masaki Oyama, Daisuke Mioki, Naoko Fujii, Sadachi Oku, Nobuyuki Muroi, Toru Hashida: Introduction and effects of an in-hospital protocol in which pharmacists answer questions about out-of-hospital prescriptions. Medical Pharmacy. 45: 82-87, 2019
  17. Yuki Nakagawa, Ikuko Miki, Naotake Takase, Tomoya Tanaka, Ayaka Miura, Tsuneo Hamaguchi, Yujiro Takao, Makoto Katsuya, Yasuhiro Mitsui, Nobuyuki Muroi: Side effects of direct-acting antivirals (DAAs). Consideration of the situation and risk factors. Journal of Japanese Medicine. 55: 177-182, 2019
review
  1. Toru Hashida: The first step is essential for training talented pharmacists who are active in the medical field. Pharmaceutical Education. 2: 113-116, 2018
  2. Hiroaki Ikesue: Drug therapy management from hospitalization to perioperative period and post-discharge. 29: 4-8, 2019
  3. Ikesue, H.: Adjuvant drugs for cancer treatment. Pharmaceutical journal special issue. New drug prospects 2019.

2017 Magazine announcement
book
  1. Toru Hashida, Hiroaki Nishioka (editors)
  2. Pharmacist Resident Manual 2nd Edition. Igaku Shoin, Tokyo, 2018
  3. Hiroaki Ikesue (partial author). Chitetsu Yoshimura, Kazuo Tamura (supervision) Edema. Cancer Drug Therapy Side Effects Management Manual, Igakushoin, Tokyo, 103-9, 2018
  4. Hiroaki Ikesue, Masaki Hirahata (partial author). Japanese Society of Pharmaceutical Health Care and Sciences (editor) Prostate cancer. Understanding and assembling pathological conditions. Disease-specific drug therapy for pharmacists I. Malignant tumor, Nankodo, Tokyo, 46-59, 2018
  5. Hiroaki Ikesue (partial author) Anti-cancer drug. Pharmacy special issue. Illness and Medicine 2018, 69: 1438-1452, Nanzando, Tokyo, 2018
  6. Hiroaki Ikesue (contributor). Yuichi Ando, Chisuke Terada (editing). Hironobu Minami (supervisor) Cancer drug therapy in a special clinical background: a case of poor PS. Cancer drug therapy handbook for high-risk patients, Yodosha, Tokyo, 296-301, 2017
paper
  1. Ikemura M, Hashida T: Effect of hyperglycemia on antitumor activity and survival in tumor-bearing mice receiving oxaliplatin and fluorouracil. Anticancer Res 37: 5463-8, 2017
  2. Nanjo S, Hata A, Okuda C, Kaji R, Okada H, Tamura D, Irie K, Okada H, Fukushima S, Katakami N: Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer 118: 32-7, 2018
  3. Uchida M, Nakamura T, Makihara Y, Suetsugu K, Ikesue H, Mori Y, Kato K, Shiratsuchi M, Hosohata K, Miyamoto T, Akashi K: Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy. 73: 304-8, 2018
  4. Kusuda, K., Nishioka, K., Ikemura, M., Higashibeppu, N., Nishioka, A., Hashida, T.: Effect of gastric acid secretion inhibitors on diarrhea-improving effect of concentrated liquid diet containing pectin. Japanese Journal of Parenteral and Enteral Nutrition 32: 988-91, 2017
  5. Mai Ikemura, Motozumi Ando, Toru Hashida: Proposal of a support method for clinical research by pharmacists. Pharmaceutical Education 1: 2017
  6. Hatanaka Y, Miura R, Nagata K, Oku Sada, Ikesue H, Fujimoto D, Iwamoto Y, Nakagawa J, Ueno S, Mitsuishi T, Okushin H, Tomii K, Hashida T: Interaction between febuxostat and azathioprine A case of pancytopenia induced by action. Japanese Journal of Hospital Pharmacists 54: 53-6, 2018
  7. Nobuko Takayanagi, Masahiro Okuno, Yoshiyasu Kubo, Akiko Hashimoto, Yasuhiro Tanaka, Toshio Takafuta, Isaki Niisato, Hiroaki Ikesue, Manabu Nakata: Influence of prescription suggestions from pharmacists attending doctor 's examinations on lenalidomide treatment. Japanese Journal of Hospital Pharmacists 54: 167-74, 2018
review
  1. Oku, S.: Answering patients' questions about medicines Medicine Q&A (1) Insulin injection. Monthly Diabetes Life Sakae 58: 23, 2018
  2. Shigefumi Morimoto: Great expectations for this season's Chemo League. Professional Cancer Nursing 7: 14-5, 2017
  3. Shigefumi Morimoto: Big expectations for this season's Kemo League. The director talks about cancer-specific team strategies! Cancer Chemotherapy Drug Player Directory. Professional Cancer Nursing 7: 45-7, 2017

2016 Magazine announcement
book
  1. Tsuyoshi Aoyama, Kanako Higashi, Hiroaki Ikesue, Kazuyoshi Kawakami, Junya Sato, Hironobu Hashimoto (Editor). Toshihiro Hama (Supervisor)
    Cancer chemotherapy regimen management manual 2nd edition. Igaku Shoin, Tokyo, 2016
  2. Hiroaki Ikesue (partial author), Yutaka Furukawa (editor)
    Basics and therapeutic agents for malignant neoplasms. Anticancer drugs.
  3. Illness and Medicine 2016, Pharmacy Special Edition, Nanzando, Tokyo, 1342-55, 2016
paper
  1. Rumiko Shimizu, Haruki Torii, Daisuke Yasuda, Yoshinori Hiraoka, Yutaka Furukawa, Akihiro Yoshimoto, Toshio Iwakura, Naoki Matsuoka, Keisuke Tomii, Nobuo Kohara, Tohru Hashida, Noriaki Kume: Comparison of serum lipid management between elderly and non-elderly patients with and without coronary heart disease (CHD). Prev Med Rep 4: 192-8, 2016
  2. Kimitaka Suetsugu, Hiroaki Ikesue, Toshihiro Miyamoto, Motoaki Shiratsuchi, Nanae Yamamoto-Taguchi, Yuichi Tsuchiya, Kumi Matsukawa, Mayako Uchida, Hiroyuki Watanabe, Koichi Akashi, Satohiro Masuda: Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Int J Hematol 105: 361-8, 2017
  3. Kaori Kanemitsu, Shigefumi Morimoto, Noriaki Kitada, Wasaburo Kataoka, Takuya Aoki, Shinya Yoshioka, Masato Kita, Toru Hashida: A study on the necessity of recommending rubella vaccination based on rubella antibody titers in pregnant women. Iryo pharmacy 42: 687-93, 2016
  4. Sugiyama Y, Ikemura M, Oku Sadatomo, Iwakura T, Hashida T: Evaluation of glycemic control by switching from existing long-acting insulin to insulin degludec in patients with type 1 diabetes mellitus. Iryo pharmacy 42: 562-8, 2016
  5. Ishida S, Takeda M, Ogawa R, Nakajima T, Ikesue H, Watanabe H, Kanaya A, Egashira N, Masuda T: Development of a quick reference table for injection formulation changes in intensive care units and evaluation of its usefulness. 286-94, 2016
  6. Narumi Kanokogi, Ohtaku Suetsugu, Atsushi Takada, Hiroaki Ikesue, Hiroyuki Watanabe, Mion Fukuda, Yuriko Ryokai, Akiko Kanaya, Nobuaki Egashira, Satosaki Masuda: Improving the efficiency of drug information management guidance at the time of discharge by constructing an IT support system. Japanese Journal of Hospital Pharmacists 52: 882-6, 2016
review
  1. Ikesue H, Hata K, Ryokai Y, Ohata S, Suetsugu O, Watanabe H, Masuda T: Occurrence timing and risk factors for hypocalcaemia associated with denosumab, a therapeutic agent for cancer bone metastasis. Advances in Clinical Pharmacology 142-8 , 2016

2015 Magazine announcement
book
  1. Toru Hashida, Hiroaki Nishioka (editors). Cardinal Rule of Pharmacist Resident, Igaku Shoin, Tokyo, 2016
paper
  1. Mai Ikemura, Shinji Nakasako, Ryutaro Seo, Takahiro Atsumi, Koichi Ariyoshi, Tohru Hashida: Reduction in gastrointestinal bleeding by development and implementation of a protocol for stress ulcer prophylaxis: a before-after study. J Pharm Health Care Sci 1: 33, 2015
  2. Rumiko Shimizu, Haruki Torii, Daisuke Yasuda, Yoshinori Hiraoka, Noriaki Kitada, Tohru Hashida, Akihiro Yoshimoto, Toru Kita, Noriaki Kume: Serum Lipid Goal Attainment in Chronic Kidney Disease (CKD) Patients under the Japan Atherosclerosis Society (JAS) 2012 Guidelines. A Single-Center Study. J Pharm Health Care Sci 22: 949-57, 2015
  3. Hirohito Hama, Shoji Tanaka, Toru Hashida: Decontamination effect of anticancer drug-contaminated environment using ozonated water and sodium hypochlorite. Japanese Journal of Medical Pharmaceutical Sciences 41: 740-49, 2015
  4. Mai Ikemura, Toru Hashida: Evaluation of research experience based on a postgraduate course aimed at fostering Pharmacist-Scientists. YAKUGAKU ZASSHI 135: 131-7, 2016
review
  1. Mieko Ooto Delirium Special Part-1 Why? Why Delirium Care Is Important. Nurse Senka 1: 16-9, 2016
  2. Ooto, Mieko Special issue on delirium PART-3 Let's identify delirium from risk factors. Nurse Senka 1: 33-4, 2016
2015 academic conference presentations and lectures
  1. Hashida T：Special Lecture II The New Role Required for Pharmacists in Cancer Pharmacotherapy. The 13th China-Japan-Korea (CJK) Joint Symposium for Clinical Information on Parenteral Drugs in Kyoto，2015.4.18
  2. Motozumi Ando, Eriko Kobiki, Shinji Nakasako, Hiroko Kashiwagi, Noriaki Kitada, Shigefumi Morimoto, Hiroki Kamei, Yumi Sono, Hiroaki Nishioka, Tsuyoshi Fukuda, Tohru Hashida: Safety and pharmacokinetics of daptomycin in Japanese patients, IATDMCT 2015, Rotterdam, 2015.10.11 -15
  3. Toru Hashida: Outpatient Pharmacist for Cancer Patients -Including Tips for Calculating Guidance and Management Fees for Cancer Patients-, Nagoya Clinical Pharma Symposium, Nagoya, 2015.21
  4. Yuriko Sugiyama, Mai Ikemura, Satoru Okusada, Toshio Iwakura, Toru Hashida: Study on switching from twice daily administration of existing sustained-release insulin to once daily administration of degludec in type 1 diabetic patients. The 58th The Japan Diabetes Society Annual Scientific Meeting, Shimonoseki, 2015.5.21-24
  5. Chiyo Yamamoto: Aiming to improve drug adherence in Hyogo Prefecture treatment - the current situation of outpatient pharmacists at our hospital -.
  6. Toru Hashida: Expectations for pharmacists who will be responsible for future medical care, 2015 National Saiseikai Hospital Pharmacist Association Workshop, Osaka, 2015.5.30
  7. Toru Hashida: The Role of Cancer Pharmacists in Cancer Drug Treatment, Osaka University of Pharmaceutical Sciences 8th Public Symposium, Takatsuki, 2015.6.5
  8. Toshihiko Inazumi: The role of pharmacists in the palliative care team of acute care hospitals.
  9. Toru Hashida: Career path of a pharmacist starting from a pharmacist resident, Annual meeting of the Japanese Society of Health Management, Osaka, 2015.6.13
  10. Haruna Yamamoto: Side effects of two-drug oral treatment with daclatasvir and asunaprevir for hepatitis C. The 30th Higashi-Kobe Gastrointestinal Disease Seminar, Kobe, June 18, 2015.
  11. Toru Hashida: Aiming to become a pharmacist active at the forefront of medical care, Meijo University Faculty of Pharmacy Dream and Discovery Seminar, Nagoya, 2015.6.20
  12. Satoshi Okusada: A pharmacist connects seamless drug treatment from pre-hospitalization to discharge. Workshop of the National Association of Pharmacy Managers of City Hospitals, Kobe, July 3, 2015.
  13. Toru Hashida: Total management of anticancer drugs - zero exposure and rewarding workplace -, The 1st Meeting of the Japanese Society of Drug Safety, Fukuyama, 2015.7.4-5
  14. Moena Miyasaka, Mieko Oone, Shigefumi Morimoto, Satoko Ito, Noboru Kitamura, Toru Hashida: Intervention by pharmacists for patients using yokukansan in the delirium team. Medical Pharmacy Forum, Nagoya, 2015.7.4-5
  15. Naoki Shibatani, Eriko Kobiki, Satoshi Okusada, Shigefumi Morimoto, Toru Hashida: Introduction of practical training program using the roof tile method for training pharmacists with practical ability. Medical Pharmacy Forum, Nagoya, 2015.7.4-5
  16. Toru Hashida: Mechanism and People Supporting Safety of Drug Treatment, The 40th Kagawa Prefectural Clinical Pharmacist Workshop, Takamatsu, 2015.7.21
  17. Toru Hashida: A new pharmacy business that realizes seamless drug treatment - outpatient pharmacist and regional cooperation -, 2015 Hiroshima pharmacist workshop, Hiroshima, 2015.7.26
  18. Shigefumi Morimoto: Clinical questions from the point of view of work -The road to clinical research and establishment of a data center-. Hanshin Area Pharmacy Seminar, Nishinomiya, 2015.7.29
  19. Kaori Yamamoto: The role of a pharmacist who supports outpatient treatment-all for cancer patients! ~. The 25th Annual Meeting of the Kansai Injection Practical Forum, Osaka, August 8, 2015
  20. Satoshi Okusada: Pharmaceutical management and pharmacist work.Introduction to Kobe City College of Nursing Training Department of Pharmacy, Kobe, September 9, 2015
  21. Okusada, S., Tomita, R., Nishihama, T., Masumoto, N., Muguruma, R., Tsujimoto, T.: Verification of the activities of the Hyogo Prefecture Federation of Diabetes Educators: Training and educational effects based on the results of a questionnaire survey. The 4th Annual Meeting of the Japanese Society of Medicine and Diabetes Annual meeting, Niigata, September 26-27, 2015
  22. Nakayaku Shinji: Factors affecting the efficacy of antimicrobial agents, drug interactions, and TDM. Japanese Nursing Association, 2015 Infection Control Certified Nurse Education Course, Kobe, 2015.9.29.
  23. Mieko Ohne, Yukari Satsuma, Toshihiko Inazumi, Setsuko Umeda, Mio Li, Toru Hashida: Efforts of our hospital toward the safe use of fentanyl citrate sublingual tablets and their usefulness. The Pharmaceutical Society of Japan, Yokohama, 2015.10.2-4
  24. Misao Sakuma, Satoshi Okusada, Kiyomi Shigehira, Miyako Mizumoto, Yoshiko Tomizawa, Kenji Uriuhara: Drug risk avoidance by interdisciplinary collaboration in pre-hospital examination center: Early intervention and its evaluation by collaboration of nurses and pharmacists in the perioperative period ~. The 54th Annual Meeting of the Japanese Association of Municipal Hospitals, Hakodate, 2015.10.8-9
  25. Satoshi Okusada: Types and usage of diabetes drugs (oral) - Patient guidance methods - Diabetes Seminar, Hyogo Prefecture Association of Diabetes Educators, Kobe, October 11-12, 2015
  26. Satoshi Okusada: Rethinking the relationship with diabetes patients. DM FLAG in Hyogo, Kobe, 2015.10.15
  27. Kazuko Nobori: Considering secondary prevention of cardiovascular disease -from the perspective of a pharmacist-.
  28. Shinji The Japanese Association for Infectious Diseases: Pharmacokinetics of antibiotics that should be noted in clinical practice (educational lecture).
  29. Masaki Hirahata: Aiming to maximize therapeutic effects through appropriate side-effect management -Efforts at each facility-.
  30. Toru Hashida: Pharmacy Department Management in Acute Hospitals - Strategies and Functions for Dealing with Rapidly Changing Medical Environment -, 1st Kumamoto City Public Hospital Pharmacy Director Management Conference, Kumamoto, 2015.10.27
  31. Toru Hashida: Symposium, The practice of cancer drug therapy to support employment, The 53rd Annual Meeting of the Japan Society of Clinical Oncology of Oncology, Kyoto, 2015.10.29-31
  32. Mieko Ooto: Ideas to prevent incidents due to delirium care ~Role of pharmacists in the delirium team~ Hyogo Prefecture Nursing Association Branch Joint Workshop (Kobe Chubu), Kobe, 2015.11.14
  33. Ikemura M, Nakayoku S, Fujiwara H, Fujiwara M, Doi M, Seo R, Atsumi I, Ariyoshi K, Hashida T: Improvement of stress ulcer prophylaxis by protocol-based pharmacotherapy management. Meeting, Yokohama, 2015.11.21
  34. Takase Y, Doi M, Fujiwara H, Tobiko K, Morimoto S, Hayasaka T, Ueda K, Ikemura M, Hashida T: PT-INR can be controlled by combination of warfarin, bucolome and amiodarone in response to metabolic enzyme induction by rifampicin 1 case.
  35. Haruna Yamamoto, Kaori Yamamoto, Ayako Sakon, Mai Ikemura, Hiroshi Tei, Yoshiki Suginoshita, Tetsuro Inokuma, Toru Hashida: Establishment and Evaluation of Outpatient Pharmacists for Hepatitis C Interferon-free Patients, Vol. 25th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Yokohama, 2015.11.22
  36. Toru Hashida: Pharmacy services from pre-hospitalization to perioperative period, transfer and discharge, The 25th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Yokohama, 2015.11.21-23
  37. Toru Hashida: Utilization of outpatient pharmacist aiming to improve anticancer drug adherence, The 25th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Yokohama, 2015.11.21-23
  38. Toru Hashida: Seamlessly connecting pharmacotherapy from inpatient/outpatient to community, The 8th Academic Lecture Meeting of Kyoto Pharmaceutical Association Maizuru District, Maizuru, 2015.11.25
  39. Mieko Ohne: The role of pharmacists in the delirium team. Osaka Pharmaceutical Association Delirium Lecture, Osaka 2015.11.27
  40. Haruna Yamamoto: Efforts of hospital pharmacists for hepatitis C interferon-free treatment and cooperation with demand pharmacies.Hyogo Hospital Pharmacists Association Hepatitis C Pharmacist Seminar 2015, Hyogo Prefecture, 2015.11.27
  41. Satoshi Okusada: Rethinking the relationship with diabetes patients. The 2nd Awaji Pharmacist Team Conference, Awaji, Hyogo Prefecture, December 3, 2015.
  42. Masaki Hirabatake: CDTM in Cancer Chemotherapy. 6th University-Medical Collaboration Lecture (Kobe Gakuin University), Kobe, 2015.12.4
  43. Toru Hashida: Responding to growing needs of ward pharmacists, Shinshu ward pharmacist seminar, Matsumoto, 2015.12.11
  44. Shimizu, Risa, Shibatani, Naoki, Ikemura, Mai, Okusada, Satoshi, Morimoto, Shigefumi, Hashida, Toru: Practical training programs prior to the new model core curriculum for pharmacy education and their issues. .23-24
  45. Misao Sakuma, Yukako Yoshino, Satoshi Okusada, Mai Ikemura, Kiyomi Shigehira, Miyako Mizumoto, Yoshiko Tomizawa, Shigefumi Morimoto, Kenji Uryuhara, Toru Hashida: doctor and nurses for pharmacist early intervention for regular drugs before hospitalization・Evaluation of pharmacists.

2014 Magazine announcement
book
  1. Kaori Kanemitsu (partial writing), Yutaka Furukawa (editing)
    Specifics II 48 key points for smooth ward work 1. Bringing medication management 1-3. Perioperative period. Ward Pharmacy Handbook, Jiho, Tokyo, 59-61, 2014
  2. Noriaki Kitada (partial writing), Yutaka Furukawa (editing)
    Detailed discussion II 48 key points for smooth ward operations 5. Protocol creation. Ward Pharmacy Handbook, Jiho, Tokyo, 86-7, 2014
  3. Shigefumi Morimoto (partial author), Yutaka Furukawa (editor)
    Detailed discussion II 48 key points for smooth ward work 6. Side effect monitoring 6-2.Evaluation and recording by CTCAE. Ward Pharmacy Handbook, Jiho, Tokyo, 94-5, 2014
  4. Shinji Nakayu (partial writing), Yutaka Furukawa (editing)
    Detailed discussion II 48 key points for smooth ward operations 7. Coordination with other occupations 7-2. Rapid information sharing and teamwork formation. Ward Pharmacy Handbook, Jiho, Tokyo, 100-4, 2014
paper
  1. Morimoto, S., Miyabe, T., Inoue, A., Hata, H., Tanijima, H., Maeda, T., Shono, Y., Nakatani, F., Fujita, Y., Yamazaki, K., Horiuchi, T.: Early hematotoxicity and nutritional assessment index PNI due to mFOLFOX6 therapy. Surgery and Metabolism/Nutrition 48: 59-67, 2014
  2. Haruna Yamamoto, Noriaki Kitada, Naoki Shibatani, Masaki Hirabatake, Toru Hashida: Points to note for risk minimization activities at the time of introduction of new drugs and the role of pharmacists. Pharmaceutical informatics 16: 28-32, 2014
  3. Tanaka T, Takeuchi M, Hashida T, Kotake K, Uchikawa S, Imaizumi Y: Effects of promotion of ward pharmacy work on drug management instruction work and drug-related incidents. Journal of the Japanese Society of Hospital Pharmacists 50: 1226-9, 2014
Review, etc.
  1. Miyuki Sakurai, Setsuko Anan, Hiromasa Ishimaru, Chiga Fujii, Shigefumi Morimoto, Sumiyo Iwamoto, Hitoshi Yoshida: Fiscal 2013 Scientific Committee 7th Scientific Subcommittee Report Investigation and research toward the creation of guidelines for the safe handling of anticancer drugs (final presentation). Japanese Journal of Hospital Pharmacists 50: 1065-71, 2014
  2. Toru Hashida: Pharmacist Resident System Current Situation in Japan and Efforts at Our Hospital. Journal of the National Municipal Hospital Council 53: 881-6, 2014
  3. Mai Ikemura, Toru Hashida: [Dosage forms and proper use of therapeutic drugs for neurological disorders] Pharmaceutical characteristics of tablets and extended-release tablets. Brain Medical 26: 95-102, 2014
  4. Toru Hashida: Pharmacy management with a view to hospital missions. Pharmacy 65: 2574-80, 2014
  5. Toru Hashida: [Medical safety that surgeons should know] Active involvement of pharmacists in medical safety. Gastroenterological Surgery 37: 1703-10, 2014
  6. Toru Hashida: [Role of hospital pharmacists in team medical care] Roles of hospital pharmacists in outpatient team medical care and human resource development. Hospital 73: 779-83, 2014
  7. Toru Hashida: [Practical hints for pharmacist education - Developing pharmacist skills!] Education for new and young employees learned from the resident program The resident system in Japan and the case of Kobe City Medical Center General Hospital. Monthly Pharmaceutical Affairs 56: 1969-75, 2014
  8. Oku, S., Hashida, Toru: Pharmaceutical intervention for perioperative patients (aiming for seamless involvement): points of pharmacological management: preoperative (outpatient/prehospital). Monthly Pharmaceutical Affairs 57: 27-33, 2015
2014 academic conference presentations and lectures
  1. Tamaki, R., Mori, A., Yanagihara, G., Amano, F.: Biology and Pathology of Chemotherapeutic treatment for Gastric scirrhous cancer. Drug Discovery & Therapy World Congress 2014, Boston (USA), 2014.06.18
  2. Chiyo Yamamoto, Kei Irie, Yu Okada, Yuichiro Ono, Naoko Hashimoto, Takayuki Ishikawa, Toru Hashida: Effect of Neurokinin-1 Receptor Antagonist on Tacrolimus Concentration in Allogeneic Stem Cell Transplantation. The 3rd International Symposium of Training Plan for Oncology Professionals, Osaka, 2015.02.07
  3. Toshihiko Inazumi: A case of cancer of unknown primary that was difficult to spend in the supine position due to low back pain. The 15th Hanshin Palliative Pharmacotherapy Network, Amagasaki, 2014.04.08
  4. Sadatomo Oku: Consciousness and efforts of medical staff regarding sugar-restricted diets: pharmacist's response based on questionnaire survey results. Lecture at the 13th Hyogo Prefecture Association of Diabetes Educators, Kobe, 2014.04.19
  5. Shigefumi Morimoto: What I learned from calculating cancer patient guidance and management fees I. 3rd Active Pharmacist Seminar in HYOGO, Kobe, 2014.05.16
  6. Masaki Hirabatake, Toru Hashida: Report on current status and issues of antiemetic therapy for moderately emetogenic anticancer drugs. 6th JSOPP, Tokyo, 2014.05.18
  7. Morimoto, S., Hata, Y., Miyabe, T., Yamazaki, K.: Report on the current status and issues of exposure control. The 6th Annual Meeting of the Japanese Society of Pharmacognosy of Cancer (JSOPP), Tokyo, 2014.05.18
  8. Masaki Hirahata: Drug treatment management and prescription proposal based on agreement between doctor and pharmacists. 2014 National, Public and Private University Hospital Medical Technology Staff Training, Tokyo, 2014.05.29
  9. Masaki Hirahata: Cancer medicine and pharmacology. Cancer Nursing Training, Kobe, 2014.05.29
  10. Toru Hashida: Active involvement of pharmacists in medical safety. 1st Multiprofessional Interdisciplinary Symposium of Japan Society for Medical Safety, Osaka ，2014.05.31
  11. Toru Hashida: Missions and Challenges of a New Era Pharmacist. Chiba Prefecture Hospital Pharmacist Summit, Chiba, 2014.6.14
  12. Shigefumi Morimoto: My Encounter with Clinical Research and Why I Want to Continue. The 3rd University-Medical Collaboration Lecture, Kobe, 2014.07.04
  13. Toru Hashida: Construction and current situation of pharmacist outpatient clinics. Ehime Prefectural Hospital Pharmacist Association Lecture, Matsuyama, 2014.7.5
  14. Shinji Nakayoku: To become a disaster-resistant pharmacist -Learn from experience and prepare for the next time-. Lecture hosted by Hyogo Prefecture Pharmacist Association Training Department, Kobe, 2014.07.13
  15. Shinji Nakayoku, Motozumi Ando, Makoto Sono, Yoko Asaka, Akira Inoue, Ryutaro Seo, Ikuhiro Atsumi, Koichi Ariyoshi, Noriaki Kitada, Shigefumi Morimoto, Toru Hashida: Chronological Study of Drug Concentrations in Patients Taking Overdose Amlodipine 1 case measured at . The 36th Annual Meeting of the Japanese Society for Clinical Toxicology, Tokyo, 2014.07.25
  16. Morimoto, Shigefumi: Side effect management. Lung Cancer Team Medical Care Promotion Forum (Japan Lung Cancer Society), Osaka, 2014.07.27
  17. Tanihara, A., Fujiwara, A., Okusada, Kanako, Oku, S., Nishida, A., Kitada, N., Kadomoto, M., Koike, M., Hashida, T. Survey on ophthalmic drug compliance guidance by pharmacists and preparation of explanatory documents for ophthalmic drugs for patients. evaluation. The 5th Annual Meeting of the Japanese Society of Applied Therapeutics, Kobe, 2014.08.02
  18. Rie Tamaki: Current status and problems in clinical trials from the perspective of CRC. Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) Summer Seminar Thinking about clinical trials in gastrointestinal cancer, Osaka, 2014.08.09
  19. Yuko Yagi, Masaki Hirabatake, Hiromichi Nomura, Shinya Nakanishi, Noriaki Kitada, Akihito Tsuji, Takayuki Ishikawa, Keisuke Tomii, Toru Hashida: Efforts and evaluation of pharmacy department for hepatitis B caused by immunosuppression and chemotherapy. The 52nd Annual Meeting of the Japan Society of Clinical Oncology of Oncology, Yokohama, 2014.08.30
  20. Kaori Yamamoto: Fact-finding survey on changes in blood coagulability in patients concomitant with S-1 and warfarin. The 52nd Annual Meeting of the Japan Society of Clinical Oncology of Oncology, Yokohama, 2014.08.30
  21. Shiho Sato, Shiori Yumiki, Naoki Shibatani, Shuichi Kishimoto, Noriaki Kitada, Kazuko Nishioka, Takuya Aoki, Nobuo Inotsume, Toru Hashida, Shoji Fukushima: Blood concentration of ritodrine for the treatment of threatened premature birth and genetic polymorphisms of SULT1A1 and β2 adrenergic receptors . The 64th Kinki Branch General Meeting of the Pharmaceutical Society of Japan, Kyoto, 2014.09.13
  22. Rie Tamaki, Shigefumi Morimoto, Akihito Tsuji: Cancer clinical trials and diversification of CRC work. The 15th Kansai Cancer Team Medical Study Group, Osaka, 2014.09.13
  23. Masaki Hirabatake, Hiroki Ito, Yuko Yagi, Hiromichi Nomura, Shinya Nakanishi, Akiko Matsushita, Toru Hashida: Measures against hepatitis B caused by immunosuppression and chemotherapy in post-cancer chemotherapy patients. The 1st Annual Meeting of the Japan Society for Medical Safety, Tokyo, 2014.09.21
  24. Sadatomo Oku: Usefulness of regular drug confirmation by pharmacist outpatient before hospitalization. The 1st Annual Meeting of the Japan Society for Medical Safety, Tokyo, 2014.09.22
  25. Sadatomo Oku: Linking pharmaceutical management from pre-hospitalization to discharge adjustment. The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.27
  26. Kaori Kanemitsu, Noriaki Kitada, Shigefumi Morimoto, Takuya Aoki, Masato Kita, Wasaburo Kataoka, Toru Hashida: Study on rubella vaccination in pregnant women based on rubella antibody titer. The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.27
  27. Yuko Yagi, Masaki Hirabatake, Hiroki Ito, Hiromichi Nomura, Shinya Nakanishi, Akiko Matsushita, Toru Hashida: Measures against hepatitis B caused by immunosuppression and chemotherapy in patients after hematopoietic stem cell transplantation. The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.27
  28. Masaki Hirabatake, Shigefumi Morimoto, Haruna Yamamoto, Noriaki Kitada, Toru Hashida: Requirement development and issues for cancer patient guidance and management work based on pharmacist outpatient experience. The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.27
  29. Kazuko Nobori, Toru Hashida: Pharmacists specializing in drug therapy and how to compile case summaries (cardiovascular disease). The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.27
  30. Motozumi Ando, Eriko Kobiki, Shinji Nakayoku, Yuko Kashiwagi, Noriaki Kitada, Hiroki Kamei, Satomi Sono, Hiroaki Nishioka, Tsuyoshi Fukuda, Toru Hashida: Safety of the anti-MRSA drug daptomycin and usefulness of blood concentration monitoring. The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Nagoya, 2014.09.28
  31. Nakayasu, Shinji: Factors affecting the efficacy of antimicrobial agents, drug interactions, and TDM. Nursing Association 2014 Infection Control Certified Nurse Education Course, Kobe, 2014.09.30
  32. Inazumi, T., Satsuma, Y., Sakon, A., Kongo, K., Ohne, M., Kitada, N., Umeda, S., Lee, M., Hashida, T.: Intervention and evaluation by pharmacists in the palliative care outpatient clinic, 2nd report. The 8th Annual Meeting of the Japanese Society of Palliative Medicine, Matsuyama, 2014.10.04
  33. A. Sakon, Y. Satsuma, M. Oon, T. Inazumi, N. Kitada, S. Umeda, Mio Li, T. Hashida: Evaluation of adjuvant analgesic effect and safety of duloxetine hydrochloride in cancer patients. The 8th Annual Meeting of the Japanese Society of Palliative Medicine, Matsuyama, 2014.10.04
  34. Sadatomo Oku: Diabetes seminar lecture Diabetes drug (oral). Diabetes Educator Hyogo Prefecture Association "Diabetes Seminar", Kobe, 2014.10.12
  35. Shigefumi Morimoto: What I learned from calculating cancer patient guidance and management fees II. 10th Kansai Psycho-Oncology Study Group, Osaka, 2014.10.31
  36. Toru Hashida: A paradigm shift in pharmacy work with expertise, The 56th Public Symposium of the Japanese Society of Pharmaceutical Health Care and Sciences, Sapporo, 2014.11.01
  37. Oku, S., Tomita, R., Nishihama, T., Masumoto, N., Muguruma, R., Tsujimoto, T.: Awareness survey on the early introduction of insulin injections. The 3rd Annual Meeting of the Japanese Society of Medicine and Diabetes, Fukuoka, 2014.11.02
  38. Sugiyama Y, Ikemura M, Oku Sadatomo, Kitada N, Iwakura T, Hashida T: Efficacy and safety of insulin degludec in patients with type 1 diabetes. The 3rd Annual Meeting of the Japanese Society of Medicine and Diabetes, Fukuoka, 2014.11.02
  39. Toru Hashida: Management of pharmacy business shifting to outpatient. Osaka Municipal Hospital Pharmacy Director Academic Lecture, Osaka, 2014.11.7
  40. Toru Hashida: Outpatient pharmacist for cancer patients. Kansai Clinical Pharma Symposium, Osaka, 2014.11.08
  41. Shigefumi Morimoto: Practical guidance and management of cancer patients based on pharmacological knowledge. Hyogo Oncology Pharmacy Seminar, Kobe, 2014.11.12
  42. Nakayaku, S.: The role of pharmacists in disaster medicine. The 62nd Annual Meeting of the Japanese Society for Occupational Accident Medicine, Kobe, 2014.11.16
  43. Shigefumi Morimoto: The practical approach to cancer patients, such as guidance and side effects, and the role of pharmacists, making the most of hospital ward work. Osaka Prefectural Hospital Pharmacists Association 2014 2nd Ward Pharmacy Workshop, Osaka, 2014.11.18
  44. Toru Hashida: Total management of anticancer drugs. Wakayama Oncology Pharmacy Seminar, Wakayama, 2014.11.22
  45. Rie Tamaki: Involvement in future clinical research. Colorectal Cancer Clinical Research Forum (CCCRF), Kobe, 2014.11.28
  46. Kazuko Nobori: Activities of certified pharmacists for HIV infection and pharmacotherapy. 2014 Hyogo Prefecture Hospital Pharmacist Workshop, Kobe, 2014.11.29
  47. Megumi Aburaya: Efficacy and Safety Evaluation of Cancer Chemotherapy in Diabetic Patients -Coordination between Basic and Clinical Studies-. 4th University-Medical Cooperation Lecture, Kobe, 2014.12.01
  48. Miho Nagai: Forward and backward coordination of pharmacotherapy. Taiho Pharmaceutical Co., Ltd. 3rd Port Island Medical and Nursing Collaboration Meeting, Kobe, 2014.12.03
  49. Naoki Shibatani, Shiho Sato, Shiori Yumiki, Ryosuke Suzuki, Shuichi Kishimoto, Noriaki Kitada, Kazuko Nishioka, Takuya Aoki, Shinya Yoshioka, Nobuo Inotume, Toru Hashida, Shoji Fukushima: Effects of β2-adrenaline on ritodrine hydrochloride in patients with threatened preterm labor Effect of receptor gene polymorphism. The 35th Annual Meeting of the Japanese Society of Clinical Pharmacology, Matsuyama, 2014.12.04
  50. Sadatomo Oku: Lecture at the 70th training session of the Hyogo Prefecture Diabetes Association Nutrition Committee. Hyogo Prefecture Diabetes Association Nutrition Committee Workshop, Kobe, 2014.12.06
  51. Toru Hashida: Preventing Human Errors in High-Risk Drugs -Cases of Anticancer Drugs-. Drug Safety Management Workshop, Tokyo, 2014.12.6
  52. Mieko Ooto: Lecture on medical safety training, ``Ingenuity to prevent incidents due to delirium''. 2014 Kobe Chuo Branch Public Interest Incorporated Association Hyogo Prefecture Nursing Association, Kobe, 2014.12.13
  53. Masaki Hirabatake: New development of pharmacist work in cancer chemotherapy. The 7th Pharmacist Seminar, Hyogo Prefecture Cancer Cooperation Council, Kobe, 2015.01.17
  54. Chihiro Noma, Sadatomo Oku, Mai Ikemura, Misao Sakuma, Shigefumi Morimoto, Noriaki Kitada, Kenji Uriuhara, Toru Hashida: Early intervention by pharmacists in drug therapy during the perioperative period and its evaluation - Medication management at pre-hospital examination centers - The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.24
  55. Sadatomo Oku: Seamless drug treatment from pre-hospitalization to post-discharge. The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.24
  56. Inazumi T: Use of acetaminophen injections in our hospital. The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.24
  57. Yuki Kasai, Masaki Hirabatake, Nanako Kawaguchi, Toru Hashida: Changes in serum calcium levels according to renal function and administration of calcium and vitamin D in patients treated with denosumab. The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.25
  58. Hidetoshi Fujiwara: Ward pharmacy work required by regional medical cooperation. The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.25
  59. Masaki Hirabatake, Shigefumi Morimoto, Haruna Yamamoto, Noriaki Kitada, Toru Hashida: Guidance and management of cancer patients based on pharmacist outpatient services. The 36th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Wakayama, 2015.01.25
  60. Masaki Hirabatake, Hiroki Ito, Yuko Yagi, Hiromichi Nomura, Shinya Nakanishi, Akiko Matsushita, Toru Hashida: Measures against hepatitis B caused by immunosuppression and chemotherapy. Kinki Block Cancer Pharmacist Forum, Osaka, 2015.02.07
  61. Tomomi Tatsumi, Mai Ikemura, Toru Hashida: Examination of bleeding frequency and background factors associated with alteplase administration. 4th Japan Pharmacist Resident Forum, Tokyo, 2015.02.07
  62. Tadashi Kazama, Motozumi Ando, Shigefumi Morimoto, Toru Hashida: A study on sex differences in hematotoxicity in R-B therapy for malignant lymphoma. 4th Japan Pharmacist Resident Forum, Tokyo, 2015.02.07
  63. Megumi Aburaya, Mai Ikemura, Toru Hashida: Fact-finding survey on the implementation of cancer chemotherapy in diabetic patients - Aiming to establish an effective and safe cancer chemotherapy -. 4th Japan Pharmacist Resident Forum, Tokyo, 2015.02.07
  64. Yuki Kasai, Masaki Hirabatake, Nanako Kawaguchi, Toru Hashida: Changes in serum calcium levels according to renal function and administration of calcium and vitamin D in patients treated with denosumab. 4th Japan Pharmacist Resident Forum, Tokyo, 2015.02.07
  65. Chihiro Noma, Sadatomo Oku, Mai Ikemura, Motozumi Ando, Misao Sakuma, Shigefumi Morimoto, Noriaki Kitada, Kenji Uryuhara, Toru Hashida: Early intervention by pharmacists in drug therapy during the perioperative period and its evaluation - pre-hospital examination center medication management in 4th Japan Pharmacist Resident Forum, Tokyo, 2015.02.07
  66. Kazumi Fujita, Mai Ikemura, Toru Hashida: Evaluation of liver deviating enzymes at the onset of phenytoin-induced liver injury. 4th Floor Japanese Pharmacist Resident Forum, Tokyo, 2015.02.07
  67. Shigefumi Morimoto: My thoughts on the functions of pharmacists in medical care. Kansai POS drug study group, Osaka, 2015.02.07
  68. Masaki Hirahata: Involvement of pharmacists in oral anticancer drugs. The 16th Nishi Municipal Hospital Drug-Drug Collaboration Open Conference, Kobe, 2015.02.10
  69. Yuriko Sugiyama: Efforts of pharmacists before hospitalization - Aiming for seamless hospitalization -. The 15th Kobe Diabetes Team Medical Study Group, Kobe, 2015.02.13
  70. Chihiro Sugihara, Sachiko Muranaka, Yuji Agawa, Eriko Kobiki, Mariko Takenaka, Naoki Higashibeppu, Hiroaki Nishioka: Report on ward NST activities at a stroke center. The 30th Annual Meeting of the Japanese Society for Parenteral and Enteral Nutrition, Kobe, 2015.02.13
  71. Hashida, Toru: Creating a Safe and Rewarding Workplace - Strategy for Zero Exposure to Anticancer Drugs and Career Considerations -. Osaka City University Cancer Professional Training Plan Lecture, Osaka, 2015.2.13
  72. Toru Hashida: On the seamless implementation of collaboration between diagnosis and medicine, which is now required of pharmacists. Osaka Pharmaceutical University 7th Cancer Pro Symposium, Takatsuki, 2015.2.15
  73. Shinji Nakayasu: Pharmacokinetics of drugs, interactions, blood concentration measurement of drugs. Japanese Nursing Association 2014 Infection Control Certified Nurse Training Program, Kobe, 2015.02.19
  74. Shigefumi Morimoto: Further Enhancement of Efforts toward Personalization of Cancer Drug Therapy -Looking to the Future-. National Hospital Organization 2014 training for promotion of team medical care 2 (cancer chemotherapy), Osaka, 2015.2.19
  75. Toru Hashida: Expanding and deepening needs for pharmacists - good luck for the ocean of medical care -. 2014 Aichi Kouseiren Pharmacist Association General Assembly, Nagoya, 2015.2.21
  76. Toru Hashida: Prescription Proposals and Outcomes Based on Agreement Between doctor and Pharmacists, 2014 Health Labor and Welfare Scientific Research Grants. Investigation and outcome evaluation symposium on team medical care and community medical care by pharmacists, Tokyo, 2015.2.22
  77. Shinji Nakayoku: Management of bring-your-own-medicine based on drug-drug cooperation -considering the current situation and prospects-. Hyogo Prefecture Hospital Pharmacists Association 2014 2nd Small and Medium-sized Hospital Diagnosis Department Workshop, Kobe, 2015.03.05
  78. Shigefumi Morimoto: How do pharmacists respond to “individualization” in cancer care? “Individualized” response to gastrointestinal cancer. Japanese Society of Clinical Oncology Annual Meeting 2015 Symposium 5, Kyoto, 2015.03.15
  79. Nomura H, Hirabatake M, Nakanishi S, Yagi Y, Tsuji A, Hashida T: Safety of high-dose cisplatin administration using short hydration. Japanese Society of Clinical Oncology Annual Meeting, Kyoto, 2015.03.15
  80. Toru Hashida: Considering Safe Handling of Pharmaceuticals. The 9th Hyogo Branch Academic Conference of the Japanese Society of Health Management, Ono, 2015.03.15
  81. Sadatomo Oku: ``Responsibility and trust required of pharmacists'' - For seamless drug treatment -. Web Symposium for Pharmacists, Tokyo, 2015.03.16
  82. Eriko Obiki, Naoki Shibatani, Sadachi Oku, Shigefumi Morimoto, Toru Hashida: Practical training program for training pharmacists with practical abilities. The 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe, 2015.03.26
  83. Motozumi Ando, Eriko Kobiki, Shinji Nakayoku, Yuko Kashiwagi, Noriaki Kitada, Shigefumi Morimoto, Hiroki Kamei, Satomi Sono, Hiroaki Nishioka, Takeshi Fukuda, Toru Hashida: Safety evaluation and pharmacokinetic effects of the anti-MRSA drug daptomycin Factor analysis. The 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe, 2015.03.26
  84. Masaki Hirahata: Prevention of exposure to anticancer agents and countermeasures against side effects. Osaka Rosai Hospital Open Conference, Osaka, 2015.03.26
  85. Toru Hashida: Safety management of cancer chemotherapy by pharmacists - Controlling occupational exposure to anticancer drugs and adverse reactions -. The 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe, 2015.03.26
  86. Toru Hashida: Establishment of pharmacist outpatient clinic and community medicine. The 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe, 2015.03.28
  87. Toru Hashida: The role of pharmacists required for telemedicine in the near future. The 135th Annual Meeting of the Pharmaceutical Society of Japan, Kobe, 2015.03.28

2013 Magazine announcement
book
  1. Hashida Toru, Kitada Noriaki, Harada Naoko, Nagano Toru (partial author). 11 Skin diseases, 77 Herpes zoster. Pharmacy March 2014 special issue, Drugs and tests 2014 Drug treatment and medication guidance practical guide. Nanzando, Tokyo, Japan. 990-1003, 2014
paper
  1. Noriaki Kitada, Kengo Kanamori, Ayako Konishi, Shoji Tanaka, Yoshiki Suginoshita, Tetsuro Inokuma, Toru Hashida: Elucidation of the factors affecting the treatment period for liver cancer using sorafenib. Cancer and Chemotherapy 40 : 479-82, 2013
  2. Mayumi Omichi, Noriaki Kitada, Kazuko Tobiko, Shoji Tanaka, Yoshinori Taji, Akihiro Yoshimoto, Takao Suzuki, Shoji Fukushima, Toru Hashida: Analysis of Correlation Between Mean Weekly Darbepoetin Alfa Dose and Hemoglobin Level in Peritoneal Dialysis Patients .Japanese The Japanese Society for Dialysis Therapy 46: 419-26, 2013
  3. Shinji Nakayoku, Noriaki Kitada, Kenji Yamamoto, Koichi Ariyoshi, Toru Hashida: Medical support for large-scale disaster-stricken areas -Trends in prescriptions at first-aid stations and logistical support using group pages-. 16: 589-94, 2013
Review, etc.
  1. Kitada, Noriaki, Hashida, Toru: Hospital ward pharmacy work to start from now on-obtaining hints from precedent cases-how to manage brought-in medicines. 953-7, 2013
  2. Noriaki Kitada: I understand the symptoms and how to deal with them! 9th - Side effects and management of anticancer drugs. Breast cancer. weekly PTX monotherapy. Monthly Pharmaceutical Affairs 55: 1330-6, 2013
2013 academic conference presentations and lectures
  1. Eriko Obiki, Motozumi Ando, Noriaki Kitada, Shinji Nakayu, Yuko Kashiwagi, Kenji Yamamoto, Hiroaki Nishioka, Toru Hashida: Monitoring of blood concentration of daptomycin and study on its safety. The 30th Annual Meeting of the Japan Society of TDM, Kumamoto, May 26, 2013
  2. Makiko Dohi, Mai Ikemura, Shinji Nakayado, Noriaki Kitada, Toru Hashida: Actual use of acid secretion inhibitors in patients with Clostridium difficile infection in the severe department. Medical Pharmacy Forum 2013/The 21st Clinical Pharmacy Symposium, Kanazawa, July 18, 2013
  3. Naoki Shibatani, Naoko Harada, Miho Nagai, Noriaki Kitada, Toru Hashida: Hospital ward pharmacy work support and its evaluation from the drug information room using a tablet terminal. The 16th Annual Meeting of the Japan Society for Drug Information, Nagoya, August 10, 2013
  4. Haruna Yamamoto, Noriaki Kitada, Naoki Shibatani, Masaki Hirabatake, Toru Hashida: How to provide information for minimizing risks when introducing new drugs - denosumab as an example -. The 16th Annual Meeting of the Japan Society for Drug Information, Nagoya, August 11, 2013
  5. Nomura H, Hirabatake M, Nakanishi S, Kitada N, Tsuji A, Hashida T: Factor analysis of renal injury due to high-dose cisplatin. The 11th Annual Meeting of the Japanese Society of Medical Oncology, Sendai, August 31, 2013
  6. Hitomi Mizutani, Shigeru Tsuruya, Kazuko Nishioka, Noriaki Kitada, Masaru Yamakawa, Toru Hashida: Characteristics and preparation of high-calorie transfusion in low birth weight infants. The 16th Annual Meeting of the Japanese Society for Injectable Drug Clinical Information, Nishinomiya, August 31, 2013
  7. Toshihiko Inazumi, Keisuke Kongo, Yukari Satsuma, Mieko Ooto, Noriaki Kitada, Setsuko Umeda, Mio Lee, Toru Hashida: Intervention and evaluation by pharmacists in palliative care outpatient clinics. The 7th Annual Meeting of the Japanese Society of Palliative Medicine, Chiba, September 15, 2013
  8. Tadashi Kazama, Noriaki Kitada, Yutaka Hasegawa, Toru Hashida, Tsuneo Hamaguchi: Effect of sex difference on hematotoxicity in R-CHOP therapy for non-Hodgkin's lymphoma. The 23rd Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Sendai, September 21, 2013
  9. Kanako Okusada, Chiyo Yamamoto, Kazuko Nobori, Noriaki Kitada, Takayuki Ishikawa, Toru Hashida: Necessity of pharmacist outpatient services for patients taking Bcr-Abl tyrosine kinase inhibitors. The 23rd Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, Sendai, September 21, 2013
  10. Nakanishi, M., Hirabatake, M., Nomura, H., Kitada, N., Hamada, M., Sato, K., Satake, Y., Kotake, T., Tsuji, A., Hashida, T.: Fact-finding survey of injection site injury caused by fosaprepitant and warm compress method for vascular pain. effect. The 51st Annual Meeting of the Japan Society of Clinical Oncology Clinical Oncology, Kyoto, October 25, 2013
  11. Mika Kumagai, Mai Ikemura, Shinji Nakayado, Yuko Kashiwagi, Noriaki Kitada, Toru Hashida: Effects of vancomycin powder on renal function in patients with severe infections. The 35th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Kyoto, February 1, 2014
  12. Nami Kinjo, Satoshi Oku, Mai Ikemura, Noriaki Kitada, Kenji Uriuhara, Toru Hashida: Clarification and evaluation of pharmacist intervention criteria for drug therapy in the perioperative period-Management of antithrombotic drugs at the pre-hospital examination center- . The 35th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Kyoto, February 1, 2014
  13. Takeshi Yonezawa, Satoshi Okusada, Nami Kinjo, Naoki Shibatani, Noriaki Kitada, Kenji Uryuhara, Toru Hashida: Observance of antithrombotic drug discontinuation instructions at the pre-hospital examination center. The 35th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Kyoto, February 1, 2014
  14. Nanako Kawaguchi, Naoko Harada, Naoki Shibatani, Noriaki Kitada, Tetsuro Inokuma, Toru Hashida: Occurrence of renal dysfunction and anemia in triple therapy with chronic hepatitis C. The 35th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Kyoto, February 1, 2014
  15. Ayano Hashiguchi, Hirohito Hama, Hiromi Higuchi, Noriaki Kitada, Hidehisa Masai, Toru Hashida: Construction of an electronic medical record allergy history information extraction system and its application to ward pharmacy work. The 35th Kinki Scientific Meeting of the Japanese Society of Hospital Pharmacists, Kyoto, February 1, 2014
  16. Shinji Nakayoku, Motozumi Ando, Takuro Hayashi, Akira Inoue, Koichi Ariyoshi, Noriaki Kitada, Toru Hashida: A case of bradycardia due to elevated blood levels of atenolol in an elderly patient undergoing maintenance hemodialysis. The 34th Annual Meeting of the Japanese Society for Clinical Toxicology, Western Japan, Hirakata, February 22, 2014
  17. Chiyo Yamamoto, Kanako Okusada, Kazuko Nobori, Noriaki Kitada, Kei Irie, Yutaka Okada, Nobuhiro Hiramoto, Naoko Hashimoto, Takayuki Ishikawa, Toru Hashida: Immunization of neurokinin 1 receptor antagonist administration in pretreatment for allogeneic hematopoietic stem cell transplantation Effect of inhibitors on blood concentration. The 36th Annual Meeting of the Japanese Society for Hematopoietic Cell Transplantation, Okinawa, March 8, 2014
  18. Shibatani Naoki, Nakasone Aki, Sato Shiho, Kishimoto Shuichi, Kitada Noriaki, Nishioka Kazuko, Aoki Takuya, Kita Masato, Inotsume Nobuo, Hashida Toru, Fukushima Shoji: Effects of genetic polymorphisms on systemic clearance of ritodrine in patients with threatened premature birth. The 134th Annual Meeting of the Pharmaceutical Society of Japan, Kumamoto, March 30, 2014
  19. Noriaki Kitada: Administration management of anticancer drugs. Kobe City Medical Center General Hospital Cancer Clinic Open Seminar, Kobe, September 12, 2013
  20. Ayano Hashiguchi, Hirohito Hama, Hiromi Higuchi, Noriaki Kitada, Hidehisa Masai, Toru Hashida: Construction of an electronic medical record allergy history information extraction system and application to ward pharmacy work. 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
  21. Nanako Kawaguchi, Eriko Kobiki, Naoko Harada, Naoki Shibatani, Noriaki Kitada, Toru Hashida: Occurrence of anemia and acute renal failure in chronic hepatitis C triple therapy. 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
  22. Mika Kumagai, Mai Ikemura, Haruna Yamamoto, Shinji Nakayasu, Yuko Kashiwagi, Noriaki Kitada, Toru Hashida: Effect of oral vancomycin powder administration on renal function in patients with severe infections. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
  23. Risa Shimizu, Chiyo Yamamoto, Kanako Okusada, Noriaki Kitada, Toru Hashida: After completion of pharmacist residency training program at Kobe City Medical Center General Hospital. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
  24. Yuki Kasai, Mai Sakai, Mai Ikemura, Masaki Hirabatake, Noriaki Kitada, Toru Hashida: The development of peripheral neuropathy due to subcutaneous administration of bortezomib and problems seen from the viewpoint of pharmacists. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
  25. Tatsuya Hirano, Yuki Takase, Hidetoshi Fujiwara, Noriaki Kitada, Toru Hashida: Investigation of blood concentration measurement and renal damage of Neoral® in interstitial pneumonia 2 hours after administration. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
  26. Arisa Takahashi, Miho Nagai, Masaki Hirabatake, Noriaki Kitada, Toru Hashida: Current status of measures against hepatitis B caused by chemotherapy in oral chronic myelogenous leukemia drugs. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
  27. Nami Kinjo, Takeshi Yonezawa, Satoshi Oku, Mai Ikemura, Noriaki Kitada, Toru Hashida: Introduction and evaluation of pharmacist intervention criteria for patients taking antithrombotic drugs at prehospital examination centers. The 3rd pharmacist resident exchange meeting, Nishinomiya, March 21, 2014
  28. Noriaki Kitada: Practical and Case Summary of Pharmaceutical Intervention -Gastrointestinal Cancer-. The 1st Japanese Society of Pharmaceutical Health Care and Sciences 1st lecture on how to write case summaries for cancer pharmacist certification application, Tokyo, May 19, 2013
  29. Toru Hashida: Building an organization for new development of ward pharmacy and training pharmacists, Pharmaceutical Management Meeting 2013, Tokyo, May 25, 2013
  30. Toru Hashida: Hospital duties carried out by new-generation Pharmacy, The 36th Tokushima University Postgraduate Education Public Lecture, Tokushima, June 1, 2013
  31. Toru Hashida: New business development and career paths for hospital pharmacists, Yamaguchi Prefectural Hospital Pharmacists Association Pharmaceutical Research Group, Yamaguchi, June 2, 2013.
  32. Shinji Nakayu: "Trial of blood concentration monitoring in patients receiving daptomycin", Seminar on MRSA infections, Kobe, July 10, 2013
  33. Noriaki Kitada: Team medical care in outpatient clinics - management of administration of oral anticancer drugs. The 6th Awaji Island cancer treatment collaboration promotion seminar, Sumoto, July 25, 2013
  34. Toru Hashida: Total Management of Anticancer Drugs, Kinki Block Cancer Chemotherapy Certified Pharmacist Seminar, Osaka, August 24, 2013
  35. Toru Hashida: A pharmacist of the new age who promotes team medical care, 1st post-graduate training course, Faculty of Pharmacy, Iwate Medical University, Morioka, August 25, 2013
  36. Toru Hashida: Team-based cancer care and the role of pharmacists—oncology pharmacists, 3rd Cancer Professional Symposium, Osaka University of Pharmaceutical Sciences, Takatsuki, August 26, 2013
  37. Toru Hashida: Total management of injectable anticancer drugs, The 16th Annual Meeting of the Japanese Society for Injectable Drug Clinical Information, Nishinomiya, August 31, 2013
  38. Noriaki Kitada: Administration management of oral anticancer drugs using drug-drug collaboration. The 1st Port Island Pharmaceutical Collaboration Meeting, Kobe, September 11, 2013
  39. Shinji Nakayaku: "Infection control system from pharmacist's point of view" 2013 Fall Lecture, Kansai Branch of Japan Society for Medical Informatics, 47th Regular Meeting of Kansai Medical Information Processing Conference, Osaka, September 14, 2013
  40. Toru Hashida: Building an organization for new development of ward pharmacy work and training pharmacists, Nara Hospital Pharmacists Association 93rd Academic Lecture, Nara, September 26, 2013
  41. Toru Hashida: Pharmacy Business Management and Human Resource Development -From the Perspective of Hospital Management-, Kanshin District National Hospital Pharmacists Association, 5th Pharmacy Department Managers Workshop, Tokyo, October 5, 2013
  42. Sadatomo Oku: "About pharmacotherapy for diabetes," Diabetes Education Seminar 2013 hosted by the Hyogo Prefecture Federation of Diabetes Educators, Kobe, October 14, 2013.
  43. Noriaki Kitada: Pharmaceutical management for perioperative risk avoidance. 19th Bayer Medical Pharmacy Seminar Kobe, Kobe, October 16, 2013
  44. Toru Hashida: Aiming for seamless drug treatment between hospitals and communities, Special Symposium of the Pharmaceutical Subcommittee, The 52nd National Association of Municipal Hospitals in Kyoto, October 18, 2013.
  45. Noriaki Kitada: Total management of cancer drug therapy. The 36th Okayama Prefectural Hospital Pharmacists Association Cancer Drug Therapy Study Group, Okayama, October 19, 2013
  46. Toru Hashida: New development of hospital pharmacy business - Expanding needs and human resource development -, The 38th Japanese Red Cross Clinical Pharmacy Workshop, Nagoya, November 3, 2013
  47. Toru Hashida: Total management of anticancer drugs, Hiroshima Prefectural Hospital Pharmacist Association Academic Lecture, Hiroshima, November 15, 2013
  48. Masaki Hirabatake: "Proposal for Optimal Regimen", Meet The Specialist (Eli Lilly Japan/ Hyogo Prefecture Hospital Pharmacist Association) Kobe, November 27, 2013
  49. Toru Hashida: Building an organization for new development of ward pharmacy work and training pharmacists, Saiseikai 2013 pharmacy Director workshop, Tokyo, December 13, 2013.
  50. Toshihiko Inazumi: Seamless Support for Cancer Patients -What is Required of Pharmacists- "Pain Management for Cancer Patients", 4th Hyogo Prefecture Pharmacist Association Training Department Lecture, Kobe, December 15, 2013.
  51. Shinji Nakayu, Eriko Kobiki: "Selection of Anti-MRSA Drugs and TDM," Nishi-Kobe Medical Center Clinical Laboratory Open Conference, Kobe, March 5, 2014
  52. Noriaki Kitada: Total management of cancer drug therapy. The 3rd Shiga cancer drug therapy conference, Moriyama, March 5, 2014

"Pharmacist Resident Manual 3rd Edition" Igaku Shoin, Tokyo, 2021, Toru Hashida, Hiroaki Nishioka (Editors).
For pharmacists in their first or second year after graduation, we have compiled information that is useful in the field in a crisp, pocket-sized format. General topics include dispensing, injection, DI, examination, and physical assessment. The specifics explain 52 major diseases such as cardiovascular disease, gastrointestinal disease, cancer, etc., in the order of "understanding the patient's condition → treatment (standard prescription example) → pharmacist's pharmaceutical care → points for prescription proposal". The pharmacy department and general medicine department of our hospital put all their efforts into writing this article.
"The iron rule of a pharmacist resident" Toru Hashida, Hiroaki Nishioka (Editors). Igaku Shoin, Tokyo, 2016
This is a book for pharmacists in their first and second years after graduation to develop their "practical skills" when solving clinical pharmaceutical problems. Based on educational cases and situations selected by senior pharmacists, we introduce guidelines and papers that support a deeper understanding of drug treatment. Tips for practicing evidence-based drug therapy and Pitfalls & Tips for new pharmacists are summarized as "iron rules" in an easy-to-understand manner.

Recruitment information

Business content

Fundamental to our role is the correct and safe provision of drug therapy for the benefit of our patients. We are actively promoting the digitalization of pharmacy operations, such as operating a robot dispensing room, and are working to enhance and expand ward and outpatient pharmacist operations to ensure the safety of drug therapy and improve adherence. In addition, pharmacists at the pre-hospitalization preparation center, internal medicine confirmation outpatient clinic, and community medicine promotion center support both before and after inpatient care, and provide drug therapy in consideration of the patient's lifestyle in order to connect drug therapy from the hospital to the community. , is also involved in self-reliance support. We are looking for a partner who can demonstrate creativity and put it into action. Let's work hard together.

education system

Utilizing the pharmacist resident system and training programs for new staff, we are training pharmacists with a clinical mindset by enhancing their study mindset. The guidance system is also substantial, and senior pharmacists have adopted a mentor-mentee system ("roof tile education" system) where senior pharmacists serve as consultation desks for work and academic activities. We have built a continuous educational system from practical training to post-graduation education for residents and new employees, and training for specialist pharmacists, and we value an environment where all staff can learn and grow together.

Working environment

We value an environment where our energetic staff can work together to maximize their potential.
・Each department, such as the central department and the ward department, has developed it so that it can be practiced voluntarily and cross-departmentally.
・We are using robots and IoT technology to improve the efficiency of our operations.
・We hold regular pharmacy department executive meetings, all-hands meetings, and education team meetings to share information and exchange opinions, thereby verifying pharmacist work and education effects and leading to further improvements.

message from senior

We not only provide central services such as dispensing, injections, and co-injection of anticancer drugs, but also ensure that outpatients and hospitalized patients can continue optimal drug treatment safely and securely, both before and after hospitalization. provides pharmaceutical care to The pharmacy department has many young staff members and is extremely lively, creating an environment in which it is easy to convey various opinions and ideas with the aim of improving operations. By linking questions discovered through daily work to clinical research and turning previously unknowns into known, there are chances to contribute to safer and more appropriate drug treatment. Would you like to practice drug treatment with us on the front line in collaboration with multi-professionals?
Click here for recruitment information